U.S. patent application number 09/922619 was filed with the patent office on 2002-04-04 for non-imidazole aryloxypiperidines.
Invention is credited to Apodaca, Richard, Carruthers, Nicholas I., Dvorak, Curt A., Shah, Chandravadan R., Xiao, Wei.
Application Number | 20020040024 09/922619 |
Document ID | / |
Family ID | 26918109 |
Filed Date | 2002-04-04 |
United States Patent
Application |
20020040024 |
Kind Code |
A1 |
Apodaca, Richard ; et
al. |
April 4, 2002 |
Non-imidazole aryloxypiperidines
Abstract
Substituted non-imidazole aryloxypiperidine compounds,
compositions containing them, and methods of making and using them
to treat or prevent histamine-mediated conditions.
Inventors: |
Apodaca, Richard; (San
Diego, CA) ; Carruthers, Nicholas I.; (Poway, CA)
; Dvorak, Curt A.; (San Diego, CA) ; Shah,
Chandravadan R.; (San Diego, CA) ; Xiao, Wei;
(San Diego, CA) |
Correspondence
Address: |
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
26918109 |
Appl. No.: |
09/922619 |
Filed: |
August 6, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60223768 |
Aug 8, 2000 |
|
|
|
Current U.S.
Class: |
514/235.5 ;
514/253.01; 514/326; 544/129; 544/360; 546/207 |
Current CPC
Class: |
C07D 213/74 20130101;
C07D 207/325 20130101; C07D 211/46 20130101; C07D 401/12 20130101;
C07D 207/335 20130101; C07D 211/58 20130101; C07D 235/06 20130101;
C07D 277/36 20130101; A61P 25/06 20180101; C07D 317/28 20130101;
C07C 323/25 20130101; C07D 295/096 20130101; A61P 25/28 20180101;
C07D 211/22 20130101; C07D 295/112 20130101; A61K 45/06 20130101;
C07D 213/36 20130101; C07D 233/84 20130101; A61K 31/4402 20130101;
A61P 11/06 20180101; C07D 295/088 20130101; C07D 233/42 20130101;
C07D 307/52 20130101; C07D 257/04 20130101; C07D 233/56 20130101;
C07D 239/34 20130101; A61P 25/00 20180101; C07D 333/20 20130101;
C07D 471/08 20130101; C07D 231/12 20130101; C07D 235/26 20130101;
C07D 295/135 20130101; C07D 233/54 20130101; C07D 295/205 20130101;
C07D 401/14 20130101; A61P 9/00 20180101; A61P 37/08 20180101; C07D
215/06 20130101; A61K 31/4465 20130101; A61P 25/24 20180101; A61P
27/16 20180101; A61P 25/08 20180101; A61P 43/00 20180101; C07D
249/08 20130101; C07D 233/88 20130101; C07C 217/22 20130101; A61P
25/18 20180101; C07C 335/32 20130101; A61K 31/4402 20130101; A61K
2300/00 20130101; A61K 31/4465 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
514/235.5 ;
514/253.01; 514/326; 544/360; 544/129; 546/207 |
International
Class: |
C07D 413/02; C07D 41/02;
A61K 031/5377; A61K 031/496; A61K 031/454 |
Claims
What is claimed is:
1. A compound of formula (I): 102wherein X is O; n is an integer
from 0 to 3; R.sub.5 is C.sub.1-10 alkyl, C.sub.3-8 alkenyl,
C.sub.3-8 cycloalkyl, (C.sub.3-8 cycloalkyl) C.sub.1-6 alkyl,
(phenyl)C.sub.1-6 alkyl, (phenyl)C.sub.3-8 alkenyl, or (C.sub.1-8
alkylcarbonyl)C.sub.1-8 alkyl; one of R.sub.1, R.sub.2, and R.sub.3
is G or W, wherein one of the remaining two is selected from H and
halogen, and the third being hydrogen; G is a nitrogen-containing
group selected from one of the following:--OL.sub.1Q, --L.sub.2Q,
--N(L.sub.1Q)R.sub.5, --L.sub.3C(L.sub.1Q)R.sub.6R.sub.7,
--C(L.sub.1Q)R.sub.6R.sub.7, 103 wherein: L.sub.1 is C.sub.2-6
alkylene, C.sub.3-8 cycloalkylene, C.sub.4-6 alkenylene, C.sub.4-6
alkynylene, C.sub.2-5 alkanoyl, (phenyl)C.sub.1-6 alkylene,
(naphthyl)C.sub.1-6 alkylene, (C.sub.2-5 heteroaryl)C.sub.1-6
alkylene, (phenoxy)C.sub.1-6 alkylene, or (C.sub.2-5
heteroaryloxy)C.sub.1-6 alkylene; L.sub.2 is C.sub.1-6 alkylene,
C.sub.3-8 cycloalkylene, C.sub.3-6 alkenylene, C.sub.3-6
alkynylene, C.sub.2-5 alkanoyl, (phenyl)C.sub.1-6 alkylene,
(naphthyl)C.sub.1-6 alkylene, (C.sub.1-5 heteroaryl)C.sub.1-6
alkylene, (phenoxy)C.sub.1-6 alkylene, (C.sub.1-5
heteroaryloxy)C.sub.1-6 alkylene, or (C.sub.1-5
heteroarylthio)C.sub.1-6 alkylene; L.sub.3 is C.sub.1-6 alkylene,
C.sub.2-6 alkenylene, C.sub.2-6 alkynylene, C.sub.2-5 alkanoyl,
(phenyl)C.sub.1-6 alkylene, phenyl, naphthyl, (naphthyl)C.sub.1-6
alkylene, C.sub.1-5 heteroaryl)C.sub.1-6 alkylene,
(phenoxy)C.sub.1-6 alkylene, (C.sub.1-5 heteroaryloxy)C.sub.1-6
alkylene, or C.sub.2-5 heteroaryl; L.sub.4 is C.sub.1-5 alkylene;
L.sub.5 is C.sub.1-5 alkylene; L.sub.6 is C.sub.1-5 alkylene;
L.sub.7 is C.sub.1-5 alkylene or absent; Q is --NR.sub.8R.sub.9 or
a non-aromatic C.sub.2-15 heterocyclyl ring system containing at
least one nitrogen atom and optionally between 1 and 3 additional
heteroatoms selected from O, S, and N in each ring; R.sub.6 is
independently selected from hydrogen, C.sub.1-8 alkyl, C.sub.1-6
alkoxy, C.sub.2-8 alkenyl, C.sub.3-7 cycloalkyl, (C.sub.3-7
cycloalkyl)C.sub.1-6 alkylene, C.sub.2-15 heterocyclyl, and
(C.sub.2-7 heterocyclyl)C.sub.1-6 alkylene; R.sub.7 is H, hydroxyl,
halo, C.sub.2-6 alkoxy or absent where the carbon linking L.sub.6
and L.sub.7 (or bonded to R.sub.6) participates in a double bond;
each of R.sub.8 and R.sub.9 is independently selected from
hydrogen, C.sub.1-6 alkoxy, C.sub.1-8 alkyl, C.sub.3-8 alkenyl,
C.sub.3-7 cycloalkyl, (C.sub.3-7 cycloalkyl)C.sub.1-6 alkylene,
C.sub.2-15 heterocyclyl, phenyl, (C.sub.2-15 heterocyclyl)C.sub.1-6
alkylene, and (phenyl) C.sub.1-6 alkylene; R.sub.10 is H, C.sub.1-8
alkyl, C.sub.3-8 alkenyl, C.sub.3-7 cycloalkyl, (C.sub.3-7
cycloalkyl)C.sub.1-6 alkylene, (C.sub.2-15 heterocyclyl)C.sub.1-6
alkylene, or (phenyl) C.sub.1-6 alkylene; W is --CN, --CHO,
halogen, C.sub.1-8 heterocyclyl, (C.sub.1-8 heterocyclyl)-O--,
phenoxy, phenyl, (phenyl)C.sub.1-6 alkylene-O--,
--C(.dbd.O)R.sub.x, --C(OH)R.sub.xR.sub.y, C.sub.1-8 alkyl,
C.sub.1-8 cycloalkyl, or --NR.sub.xR.sub.y; wherein each of R.sub.x
and R.sub.y is independently selected from H, C.sub.1-6 alkyl,
C.sub.1-6 alkanoyl, C.sub.1-8 heterocyclyl, and phenyl; wherein
each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl,
alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be
independently and optionally substituted with between 1 and 3
substituents selected from halo, amino, nitro, hydroxyl, and
C.sub.1-3 alkyl; wherein substituents of Q can be further selected
from carboxamide, C.sub.2-6 alkyl, C.sub.1-8 heterocyclyl,
N(C.sub.1-6 alkyl)(C.sub.1-8 heterocyclyl), NH(C.sub.1-8
heterocyclyl), (C.sub.1-3 alkylene)(C.sub.1-8 heterocyclyl),
O(C.sub.1-8 heterocyclyl), O(C.sub.1-6 alkyl), O(C.sub.3-6
cycloalkyl), phenyl, (C.sub.1-3 alkylene) phenyl, N(C.sub.1-6
alkyl)(C.sub.1-3 alkylene) phenyl, and O(C.sub.1-3 alkylene) phenyl
where each of above heterocyclyl, phenyl, and alkyl groups may be
optionally substituted with from 1 to 3 substituents independently
selected from halogen, nitro, cyano, and C.sub.1-3 alkyl; or a
pharmaceutically acceptable salt, ester, or amide thereof.
2. A compound of claim 1, wherein R.sub.5 is C.sub.1-5 alkyl,
C.sub.3-4 alkenyl, C.sub.3-6 cycloalkyl, (C.sub.3-6 cycloalkyl)
C.sub.1 alkylene, (phenyl)C.sub.1-3 alkylene, or (phenyl)C.sub.3-4
alkenylene.
3. A compound of claim 2, wherein R.sub.5 is branched C.sub.3-5
alkyl, C.sub.3-6 cycloalkyl, and (C.sub.3-6 cycloalkyl )C.sub.1
alkylene.
4. A compound of claim 1, wherein one of R.sub.2 and R.sub.3 is
G.
5. A compound of claim 4, wherein R.sub.2 is G.
6. A compound of claim 4, wherein R.sub.3 is G.
7. A compound of claim 1, wherein L.sub.1 is C.sub.2-3
alkylene.
8. A compound of claim 1, wherein L.sub.2 is C.sub.1-6 alkylene,
(C.sub.1-5 heteroaryl)C.sub.1-6 alkylene, or -phenyl-C.sub.1-6
alkylene.
9. A compound of claim 8, wherein L.sub.2 is methylene.
10. A compound of claim 1, wherein L.sub.3 is ethylene, vinylene,
ethynylene, and phenylene.
11. A compound of claim 1, wherein Q is a non-aromatic
nitrogen-containing C.sub.2-5 heterocyclyl.
12. A compound of claim 11, wherein Q is selected from piperidyl,
N--(C.sub.1-6 alkyl)piperazinyl, piperazinyl, pyrrolinyl,
pyrrolidinyl, and morpholinyl.
13. A compound of claim 11, wherein Q is N-morpholinyl or
N-piperidinyl, optionally substituted with between 1 and 3
substituents selected from hydroxyl, carboxamide, C.sub.1-6 alkyl,
C.sub.1-8 heterocyclyl, N(C.sub.1-6 alkyl)(C.sub.1-8 heterocyclyl),
NH(C.sub.1-8 heterocyclyl), (C.sub.1-3 alkylene)(C.sub.1-8
heterocyclyl), O(C.sub.1-8 heterocyclyl), O(C.sub.1-6 alkyl),
O(C.sub.3-6 cycloalkyl), phenyl, (C.sub.1-3 alkylene)phenyl,
N(C.sub.1-6 alkyl)(C.sub.1-3 alkylene)phenyl, and O(C.sub.1-3
alkylene)phenyl where each of above heterocyclyl, phenyl, and alkyl
groups may be optionally substituted with from 1 to 3 substituents
independently selected from halogen, nitro, cyano, and C.sub.1-3
alkyl.
14. A compound of claim 13, wherein Q is substituted with a
substituent comprising a C.sub.1-6 heterocyclyl group selected
from: pyridyl, pyrimidyl, furyl, thiofuryl, imidazolyl, (C.sub.1-6
alkyl) imidazolyl, oxazolyl, thiazolyl, 2,3-dihydro-indolyl,
benzimidazolyl, 2-oxobenzimidazolyl, (C.sub.1-6 alkyl) tetrazolyl,
tetrazolyl, (C.sub.1-6 alkyl) triazolyl, triazolyl, (C.sub.1-6
alkyl) pyrrolyl, and pyrrolyl.
15. A compound of claim 14, wherein Q is a substituted or
unsubstituted N-morpholinyl.
16. A compound of claim 1, wherein Q is NR.sub.8R.sub.9 wherein
each of R.sub.8 or R.sub.9 is independently selected from hydrogen,
C.sub.1-8 alkyl, C.sub.3-8 alkenyl, C.sub.3-7 cycloalkyl,
(C.sub.3-7 cycloalkyl)C.sub.1-6 alkylene, C.sub.2-6 heterocyclyl,
phenyl, (C.sub.2-5 heterocyclyl)C.sub.1-6 alkylene, and (phenyl)
C.sub.1-6 alkylene.
17. A compound of claim 16, wherein one of R.sub.8 and R.sub.9 is
hydrogen.
18. A compound of claim 17, wherein R.sub.8 is H and R.sub.9 is
phenyl or aromatic C.sub.1-8 heterocyclyl optionally substituted
with 1-3 substituents selected from halo, nitro, cyano, and
C.sub.1-3 alkyl.
19. A compound of claim 18, wherein R.sub.9 is phenyl, pyridyl,
pyrimidyl, furyl, thiofuryl, imidazolyl, (C.sub.1-8 alkyl)
imidazolyl, oxazolyl, thiazolyl, 2,3-dihydro-indolyl,
benzimidazolyl, 2-oxobenzimidazolyl, (C.sub.1-6 alkyl) tetrazolyl,
tetrazolyl, (C.sub.1-6 alkyl) triazolyl, triazolyl, (C.sub.1-6
alkyl) pyrrolyl, and pyrrolyl.
20. A compound of claim 18, wherein R.sub.5 is C.sub.1-5 alkyl,
C.sub.3-4 alkenyl, C.sub.3-6 cycloalkyl, (C.sub.3-6 cycloalkyl)
C.sub.1alkylene, (phenyl)C.sub.1-3 alkylene, or (phenyl)C.sub.3-4
alkenylene.
21. A compound of claim 1, wherein n is 0 or 1.
22. A compound of claim 21, wherein n is 0.
23. A compound of claim 1, wherein G is selected from: (4) formula
(i) wherein L.sub.4 and L.sub.5 are independently selected from
C.sub.2-3 alkylene, (5) formula (iii) wherein L.sub.6 is C.sub.2-3
alkylene and L.sub.7 is C.sub.2-3 alkylene or absent, (6) L.sub.2Q
wherein L.sub.2 is C.sub.1-6 alkylene, phenyl C.sub.1-4 alkylene,
or (aromatic C.sub.1-5 heterocyclyl)C.sub.1-4 alkylene, and (7)
OL.sub.1Q wherein L.sub.1 is C.sub.2-3 alkylene.
24. A compound of claim 23, wherein G is selected from: (8) formula
(i) wherein L.sub.4 and L.sub.5 are each C.sub.2 alkylene, (9)
formula (iii) wherein each of L.sub.6 and L.sub.7 is C.sub.2
alkylene, and (10) L.sub.2Q wherein L.sub.2 is methylene.
25. A compound of claim 24, wherein G is L.sub.2Q.
26. A compound of claim 23, wherein R.sub.10 is H, branched
C.sub.3-6 alkyl, or benzyl.
27. A compound of claim 26, wherein R.sub.10 is isopropyl or
benzyl.
28. A compound of claim 23, wherein Q is a non-aromatic C.sub.2-5
heterocyclyl.
29. A compound of claim 28, wherein Q is selected from piperidyl,
N--(C.sub.1-6 alkyl)piperazinyl, piperazinyl, pyrrolinyl,
pyrrolidinyl, and morpholinyl.
30. A compound of claim 24, wherein Q is a non-aromatic C.sub.2-5
heterocyclyl.
31. A compound of claim 30, wherein Q is selected from piperidyl,
N--(C.sub.1-6 alkyl)piperazinyl, piperazinyl, pyrrolinyl,
pyrrolidinyl, and morpholinyl.
32. A compound of claim 25, wherein Q is selected from piperidyl,
N--(C.sub.1-6 alkyl)piperazinyl, piperazinyl, pyrrolinyl,
pyrrolidinyl, and morpholinyl.
33. A compound of claim 23, wherein R.sub.5 is C.sub.1-5 alkyl,
C.sub.3-4 alkenyl, C.sub.3-6 cycloalkyl, (C.sub.3-6 cycloalkyl)
C.sub.1 alkylene, (phenyl)C.sub.1-3 alkylene, or (phenyl)C.sub.3-4
alkenylene.
34. A compound of claim 23, wherein R.sub.7 is hydroxyl, halo, or
absent where one of L.sub.6 and L.sub.7 provides a double bond to
the carbon atom to which R.sub.6 and R.sub.7 are attached.
35. A compound of claim 1, wherein one of R.sub.2 and R.sub.3 is
G.
36. A compound of claim 1, wherein one of R.sub.2 and R.sub.3 is W,
and W is a heterocyclyl selected from: pyridyl, pyrimidyl, furyl,
thiofuryl, imidazolyl, oxazolyl, thiazolyl, 2,3-dihydro-indolyl,
benzimidazolyl, tetrazolyl, triazolyl, and pyrrolyl.
37. A compound of claim 21, wherein R.sub.5 is branched C.sub.3-5
alkyl.
38. A compound of claim 21, wherein R.sub.5 is isopropyl or
cyclopentyl.
39. A compound of claim 1, selected from
4-(4-Imidazol-1-yl-phenoxy)-1-iso- propyl-piperidine,
4-(4-Imidazol-1-yl-phenoxy)-1-isobutyl-piperidine,
1-Isopropyl-4-(4-pyrrol-1-yl-phenoxy)-piperidine, and
5-Chloro-2-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-1H-benzoimidazole.
40. A compound of claim 39, selected from
4-(4-Imidazol-1-yl-phenoxy)-1-is- opropyl-piperidine,
4-(4-Imidazol-1-yl-phenoxy)-1-isobutyl-piperidine, and
5-Chloro-2-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-1H-benzoimidazole.
41. A compound of claim 1, selected from
[4-(1-Isopropyl-piperidin-4-yloxy- )-phenyl]-phenyl-methanone,
4-(Biphenyl-4-yloxy)-1-isopropyl-piperidine,
4-(4-Benzyloxy-phenoxy)-1-isopropyl-piperidine,
1-Isopropyl-4-(4-phenoxy-- phenoxy)-piperidine,
4-(4-Benzyl-phenoxy)-1-isopropyl-piperidine,
[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-phenyl-methanol,
N-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-acetamide,
4-(4-Cyclopentyl-phenoxy)-1-isopropyl-piperidine,
4-(1-Cyclopentyl-piperi- din-4-yloxy)-benzonitrile,
4-(1-Cyclobutyl-piperidin-4-yloxy)-benzonitrile- ,
4-(1-sec-Butyl-piperidin-4-yloxy)-benzonitrile,
4-(1-Isopropyl-piperidin- -4-yloxy)-benzaldehyde,
4-(1-Cyclohexyl-piperidin-4-yloxy)-benzonitrile,
4-(1-Isopropyl-piperidin-4-yloxy)-benzonitrile,
4-(1-Cyclopropylmethyl-pi- peridin-4-yloxy)-benzonitrile, and
4-(1-Isobutyl-piperidin-4-yloxy)-benzon- itrile,
4-(1-Propyl-piperidin-4-yloxy)-benzonitrile.
42. A compound of claim 1, selected from
4-(Biphenyl-4-yloxy)-1-isopropyl-- piperidine,
4-(4-Benzyloxy-phenoxy)-1-isopropyl-piperidine,
4-(4-Benzyl-phenoxy)-1-isopropyl-piperidine,
1-Isopropyl-4-(4-phenoxy-phe- noxy)-piperidine, and
N-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-acetami- de.
43. A compound of claim 1, selected from
1-Isopropyl-4-[4-(1-isopropyl-pip-
eridin-4-yloxy)-phenyl]-piperazine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-p- henyl]-piperazine, and
1-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-pipera- zine.
44. A compound of claim 1, selected from
1-[4-(1-Isopropyl-piperidin-4-ylo- xy)-benzyl]-piperidine,
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morph- oline,
1-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-N-Isopropyl-4-{4-[5-(1-isopropyl-piperidin-4-ylsulfanyl)-tetrazol-1-yl]-
-phenoxy}-piperidine,
{1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperi-
din-4-yl}-methanol,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl--
[1,4]diazepane,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperidin-4-ol,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-methyl-(1-methyl-piperidin-4-y-
l)-amine,
1-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-4-benzyl-piperidine- ,
N-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-N,N',N'-trimethyl-ethane-1,-
2-diamine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-piperazin- e,
Cyclohexyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
Butyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
4-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-Isopropyl-4-(4-pyrrolidin-1-ylmethyl-phenoxy)-piperidine,
Diethyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine,
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-phenyl-piperazine,
1-Benzyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperazine,
4-[4-(4-Benzylidene-piperidin-1-ylmethyl)-phenoxy]-1-isopropyl-piperidine-
, 4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-dimethyl-amine,
4-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-morpholine,
4-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-morpholine,
4-[4-(1-Propyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Benzyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Cyclohexylmethyl-piperidin-4-yloxy)-benzyl]-piperidine, and
4-[4-(4-Piperidin-1-ylmethyl-phenoxy)-piperidin-1-yl]-butan-2-one
45. A compound of claim 1, selected from
1-[4-(1-Isopropyl-piperidin-4-ylo- xy)-benzyl]-piperidine,
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morph- oline,
1-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-N-Isopropyl-4-{4-[5-(1-isopropyl-piperidin-4-ylsulfanyl)-tetrazol-1-yl]-
-phenoxy}-piperidine,
{1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperi-
din-4-yl}-methanol,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl--
[1,4]diazepane,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidin-4-ol,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-methyl-(1-methyl-piperidin-4-y-
l)-amine,
1-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-4-benzyl-piperidine- ,
N-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-N,N',N'-trimethyl-ethane-1,-
2-diamine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-piperazin- e,
Cyclohexyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
Butyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
4-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-Isopropyl-4-(4-pyrrolidin-1-ylmethyl-phenoxy)-piperidine,
Diethyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine,
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-phenyl-piperazine,
1-Benzyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperazine,
4-[4-(4-Benzylidene-piperidin-1-ylmethyl)-phenoxy]-1-isopropyl-piperidine-
, 4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-dimethyl-amine,
4-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-morpholine, and
4-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-morpholine.
46. A compound of claim 1, selected from
Cyclopropyl-[4-(1-isopropyl-piper- idin-4-yloxy)-benzyl]-amine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-(5-
-methyl-pyridin-2-yl)-amine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-py- ridin-2-yl-amine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-phenyl-amine, and
(5-Chloro-pyridin-2-yl)-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-am-
ine.
47. A compound of claim 1 or 23, isotopically labelled to be
detectable by PET or SPECT.
48. A pharmaceutical composition, comprising a compound of claim 1
and a pharmaceutically acceptable carrier.
49. A method of inhibiting histamine H.sub.3 receptor activity in a
subject, comprising administering an effective amount of a compound
of claim 1, 23, 45, or 46 to a subject in need of such inhibition
of histamine H.sub.3 receptor activity.
50. A method of treating a subject having a disease or condition
modulated by histamine H.sub.3 receptor activity, comprising
administering to the subject a therapeutically effective amount of
a compound of claim 1, 23, 45, or 46.
51. A method of claim 50, wherein said disease or condition is
selected from the group consisting of sleep/wake disorders,
arousal/vigilance disorders, migraine, asthma, dementia, mild
cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy,
narcolepsy, eating disorders, motion sickness, vertigo, attention
deficit hyperactivity disorders, learning disorders, memory
retention disorders, schizophrenia, nasal congestion, allergic
rhinitis, and upper airway allergic response.
52. A method for treating a disease or condition modulated by at
least one receptor selected from the histamine H.sub.1 receptor and
the histamine H.sub.3 receptor, said method comprising (a)
administering to a subject a jointly effective amount of a
histamine H.sub.1 receptor antagonist compound, and (b)
administering to the subject a jointly effective amount of a
compound of claim 1, 23, 45, or 46, said method providing a jointly
therapeutically effective amount of said compounds.
53. The method of claim 52 wherein the histamine H.sub.1 receptor
antagonist and the compound of claim 1, 23, 45, or 46 are present
in the same dosage form.
54. A method for treating diseases or conditions modulated by at
least one receptor selected from the histamine H.sub.2 receptor and
the histamine H.sub.3 receptor in a subject, comprising (a)
administering to the subject a jointly effective amount of a
histamine H.sub.2 receptor antagonist compound, and (b)
administering to the subject a jointly effective amount of a
compound of claim 1, 26, 27, or 41, said method providing a jointly
therapeutically effective amount of said compounds.
55. The method of claim 54 wherein the histamine H.sub.2 receptor
antagonist and the compound of claim 1, 23, 45, or 46 are present
in the same dosage form.
56. A method for treating one or more disorders or conditions
selected from the group consisting of sleep/wake disorders,
narcolepsy, and arousal/vigilance disorders, comprising
administering to a subject a therapeutically effective amount of a
compound of claim 1, 23, 45, or 46.
57. A method for treating attention deficit hyperactivity disorders
(ADHD), comprising administering to a subject a therapeutically
effective amount of a compound of claim 1, 23, 45, or 46.
58. A method for treating one or more disorders or conditions
selected from the group consisting of dementia, mild cognitive
impairment (pre-dementia), cognitive dysfunction, schizophrenia,
depression, manic disorders, bipolar disorders, and learning and
memory disorders, comprising administering to a subject a
therapeutically effective amount of a compound of claim 1, 23, 45,
or 46.
59. A method for treating or preventing upper airway allergic
response, nasal congestion, or allergic rhinitis, comprising
administering to a subject a therapeutically effective amount of a
compound of claim 1, 23, 45, or 46.
60. A method for studying disorders mediated by the histamine
H.sub.3 receptor, comprising using an .sup.18F-labeled compound of
claim 1 or 23 as a positron emission tomography (PET) molecular
probe.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to aryloxypiperidines, their
synthesis and their use, for example, for the treatment of
disorders and conditions mediated by the histamine receptor.
BACKGROUND OF THE INVENTION
[0002] Histamine [2-(imidazol-4-yl)ethylamine] is a transmitter
substance. Histamine exerts a physiological effect via multiple
distinct G-protein coupled receptors. It plays a role in immediate
hypersensitivity reactions and is released from mast cells
following antigen IgE antibody interaction. The actions of released
histamine on the vasculature and smooth muscle system account for
the symptoms of the allergic response. These actions occur at the
H.sub.1 receptor (Ash, A. S. F. and Schild, H. O., Br. J.
Pharmacol., 1966, 27, 427) and are blocked by the classical
antihistamines (e.g. diphenhydramine). Histamine is also an
important regulator of gastric acid secretion through its action on
parietal cells. These effects of histamine are mediated via the
H.sub.2 receptor (Black, J. W., Duncan, W. A. M., Durant, C. J.,
Ganellin, C. R. and Parsons, E. M., Nature, 1972, 236, 385) and are
blocked by H.sub.2 receptor antagonists (e.g. cimetidine). The
third histamine receptor --H.sub.3-- was first described as a
presynaptic autoreceptor in the central nervous system (CNS)
(Arrang, J.-M., Garbarg, M., and Schwartz, J.-C., Nature 1983, 302,
832) controlling the synthesis and release of histamine. Recent
evidence has emerged showing that the H.sub.3 receptors are also
located presynaptically as heteroreceptors on serotonergic,
noradrenergic, dopaminergic, cholinergic, and GABAergic
(gamma-aminobutyric acid containing) neurons. These H.sub.3
receptors have also recently been identified in peripheral tissues
such as vascular smooth muscle. Consequently there are many
potential therapeutic applications for histamine H.sub.3 agonists,
antagonists, and inverse agonists. (See: "The Histamine H.sub.3
Receptor-A Target for New Drugs", Leurs, R., and Timmerman, H.,
(Editors), Elsevier, 1998; Morisset et al., Nature, 2000, 408,
860-864.) A fourth histamine receptor --H.sub.4-- was recently
described by Oda et al., (J. Biol. Chem., 2000, 275,
36781-36786).
[0003] The potential use of histamine H.sub.3 agonists in
sleep/wake and arousal/vigilance disorders is suggested based on
animal studies (Lin et al, Br. Res., 1990, 523, 325; Monti et al
Eur. J. Pharmacol., 1991, 205, 283). Their use in the treatment of
migraine has also been suggested (McLeod et al Abstr. Society
Neuroscience, 1996, 22, 2010) based on their ability to inhibit
neurogenic inflammation. Other applications could be a protective
role in myocardial ischemia and hypertension where blockade of
norepinephrine release is beneficial (Imamura et al J. Pharmacol.
Expt. Ther., 1994, 271, 1259). It has been suggested that histamine
H.sub.3 agonists may be beneficial in asthma due to their ability
to reduce non-adrenergic non-cholinergic (NANC) neurotransmission
in airways and to reduce microvascular leakage (Ichinose et al Eur.
J. Pharmacol., 1989,174, 49).
[0004] Several indications for histamine H.sub.3 antagonists and
inverse agonists have similarly been proposed based on animal
pharmacology experiments with known histamine H.sub.3 antagonists
(e.g. thioperamide). These include dementia, Alzheimer's disease
(Panula et al Abstr. Society Neuroscience, 1995, 21,1977), epilepsy
(Yokoyama et al Eur. J. Pharmacol., 1993, 234, 129) narcolepsy,
eating disorders (Machidori et al Brain Research 1992, 590, 180),
motion sickness, vertigo, attention deficit hyperactivity disorders
(ADHD), learning and memory (Barnes et al Abstr. Society
Neuroscience, 1993,19,1813), schizophrenia (Schlicker et al
Naunyn-Schmiedeberg's Arch. Pharmacol., 1996, 353, 290-294); (also
see; Stark et al Drugs Future, 1996,21, 507 and Leurs et al
Progress in Drug Research, 1995, 45, 107 and references cited
therein). Histamine H.sub.3 antagonists, alone or in combination
with a histamine H.sub.1 antagonist, are reported to be useful for
the treatment of upper airway allergic response (U.S. Pat. Nos.
5,217,986; 5,352,707 and 5,869,479). Recently, a histamine H.sub.3
antagonist (GT-2331) was identified and is being developed by
Gliatech Inc. (Gliatech Inc. Press Release Nov. 5, 1998; Bioworld
Today, Mar. 2, 1999) for the treatment of CNS disorders.
[0005] As noted, the prior art related to histamine H.sub.3 ligands
has been comprehensively reviewed ("The Histamine H.sub.3
Receptor-A Target for New Drugs", Leurs, R., and Timmerman, H.,
(Editors), Elsevier, 1998). Within this reference the medicinal
chemistry of histamine H.sub.3 agonists and antagonists was
reviewed (see Krause et al and Phillips et al respectively). The
importance of an imidazole moiety containing only a single
substitution in the 4 position was noted together with the
deleterious effects of additional substitution on activity.
Particularly methylation of the imidazole ring at any of the
remaining unsubstituted positions was reported to strongly decrease
activity. Additional publications support the hypothesis that an
imidazole function is essential for high affinity histamine H.sub.3
receptor ligands (See, Ali et al J. Med. Chem., 1999, 42, 903 and
Stark et al, Drugs Future, 1996, 21, 507 and references cited
therein). However many imidazole containing compounds are
substrates for histamine methyl transferase, the major histamine
metabolizing enzyme in humans, which leads to shortened half lives
and lower bioavailability (See, Rouleau et al J. Pharmacol. Exp.
Ther. 1997, 281, 1085). In addition, imidazole containing drugs,
via their interaction with the cytochrome P450 monooxygenase
system, can result in unfavorable biotransformations due to enzyme
induction or enzyme inhibition. (Kapetanovic et al Drug Metab.
Dispos. 1984,12, 560; Sheets et al Drug Metab. Dispos. 1984, 12,
603; Back, et al Br. J. Pharmacol. 1985, 85, 121; Lavrijsen et al
Biochem. Pharmacol. 1986, 35,1867; Drug Saf., 1998, 18, 83). The
poor blood brain barrier penetration of earlier histamine H.sub.3
receptor ligands may also be associated with the imidazole fragment
(Ganellin et al Arch. Pharm. (Weinheim, Ger.) 1998, 331, 395).
[0006] More recently, several publications have described histamine
H.sub.3 ligands that do not contain an imidazole moiety. For
example; Ganellin et al Arch. Pharm. (Weinheim, Ger.) 1998, 331,
395; Walczynski et al Arch. Pharm. (Weinheim, Ger.) 1999, 332, 389;
Walczynski et al Farmaco 1999, 684; Linney et al J. Med. Chem.
2000, 2362; Tozer and Kalindjian Exp. Opin. Ther. Patents 2000, 10,
1045-1055; U.S. Pat. No. 5,352,707; PCT Application WO99/42458,
Aug. 26, 1999; and European Patent Application 0978512, Feb. 9,
2000.
[0007] The compounds of the present invention do not contain the
imidazole moiety, and its inherent liabilities, and maintain
potency at the human H.sub.3 receptor. Thus in the present
invention receptor binding was determined using the human histamine
H.sub.3 receptor (See Lovenberg et al Mol. Pharmacol. 1999, 1107).
Screening using the human receptor is particularly important for
the identification of new therapies for the treatment of human
disease. Conventional binding assays for example are determined
using rat synaptosomes (Garbarg et al J. Pharmacol. Exp. Ther.
1992, 263, 304), rat cortical membranes (West et al Mol.
Pharmacol., 1990, 610), and guinea pig brain (Korte et al Biochem.
Biophys. Res. Commun. 1990, 978). Only limited studies have been
performed previously using human tissue but these allude to
significant differences in the pharmacology of rodent and primate
receptors (West et al Eur. J. Pharmacol. 1999, 233).
[0008] We now describe a series of aryloxypiperidines with the
ability to modulate the activity of the histamine receptor,
specifically the H.sub.3 receptor, without the inherent problems
associated with the presence of an imidazolyl moiety.
SUMMARY OF THE INVENTION
[0009] The present invention is directed to a compound of formula
(I): 1
[0010] wherein
[0011] X is O;
[0012] n is an integer from 0 to 3;
[0013] R.sub.5 is C.sub.1-10 alkyl, C.sub.3-8 alkenyl, C.sub.3-8
cycloalkyl, (C.sub.3-8 cycloalkyl) C.sub.1-6 alkyl,
(phenyl)C.sub.1-8 alkyl, (phenyl)C.sub.3-8 alkenyl, or (C.sub.1-8
alkylcarbonyl)C.sub.1-8 alkyl;
[0014] one of R.sub.1, R.sub.2, and R.sub.3 is G or W, wherein one
of the remaining two is selected from H and halogen, and the third
being hydrogen;
[0015] G is a nitrogen-containing group selected from one of the
following:
--OL.sub.1Q, --L.sub.2Q, --N(L.sub.1Q)R.sub.5,
--L.sub.3C(L.sub.1Q)R.sub.6- R.sub.7,
--C(L.sub.1Q)R.sub.6R.sub.7,
[0016] 2
[0017] wherein:
[0018] L.sub.1 is C.sub.2-6 alkylene, C.sub.3-8 cycloalkylene,
C.sub.4-6 alkenylene, C.sub.4-6 alkynylene, C.sub.2-5 alkanoyl,
(phenyl)C.sub.1-6 alkylene, (naphthyl)C.sub.1-6 alkylene,
(C.sub.2-5 heteroaryl)C.sub.1-6 alkylene, (phenoxy)C.sub.1-6
alkylene, or (C.sub.2-5 heteroaryloxy)C.sub.1-6 alkylene;
[0019] L.sub.2 is C.sub.1-6 alkylene, C.sub.3-8 cycloalkylene,
C.sub.3-6 alkenylene, C.sub.3-6 alkynylene, C.sub.2-5 alkanoyl,
(phenyl)C.sub.1-6 alkylene, (naphthyl)C.sub.1-6 alkylene,
(C.sub.1-5 heteroaryl)C.sub.1-6 alkylene, (phenoxy)C.sub.1-6
alkylene, (C.sub.1-5 heteroaryloxy)C.sub.1-6 alkylene, or
(C.sub.1-5 heteroarylthio)C.sub.1-6 alkylene;
[0020] L.sub.3 is C.sub.1-6 alkylene, C.sub.2-6 alkenylene,
C.sub.2-6 alkynylene, C.sub.2-5 alkanoyl, (phenyl)C.sub.1-6
alkylene, phenyl, naphthyl, (naphthyl)C.sub.1-6 alkylene, C.sub.1-5
heteroaryl)C.sub.1-6 alkylene, (phenoxy)C.sub.1-6 alkylene,
(C.sub.1-5 heteroaryloxy)C.sub.1-6 alkylene, or C.sub.2-5
heteroaryl;
[0021] L.sub.4 is C.sub.1-5 alkylene;
[0022] L.sub.5 is C.sub.1-5 alkylene;
[0023] L.sub.6 is C.sub.1-5 alkylene;
[0024] L.sub.7 is C.sub.1-5 alkylene or absent;
[0025] Q is --NR.sub.8R.sub.9 or a non-aromatic C.sub.2-15
heterocyclyl ring system containing at least one nitrogen atom and
optionally between 1 and 3 additional heteroatoms selected from O,
S, and N in each ring;
[0026] R.sub.6 is independently selected from hydrogen, C.sub.1-8
alkyl, C.sub.1-6 alkoxy, C.sub.2-8 alkenyl, C.sub.3-7 cycloalkyl,
(C.sub.3-7 cycloalkyl)C.sub.1-6 alkylene, C.sub.2-15 heterocyclyl,
and (C.sub.2-7 heterocyclyl)C.sub.1-6 alkylene;
[0027] R.sub.7 is H, hydroxyl, halo, C.sub.2-6 alkoxy or absent
where the carbon linking L.sub.6 and L.sub.7 (or bonded to R.sub.6)
participates in a double bond;
[0028] each of R.sub.8 and R.sub.9 is independently selected from
hydrogen, C.sub.1-6 alkoxy, C.sub.1-8 alkyl, C.sub.3-8 alkenyl,
C.sub.3-7 cycloalkyl, (C.sub.3-7 cycloalkyl)C.sub.1-6 alkylene,
C.sub.2-15 heterocyclyl, phenyl, (C.sub.2-15 heterocyclyl)C.sub.1-6
alkylene, and (phenyl) C.sub.1-6 alkylene;
[0029] R.sub.10 is H, C.sub.1-8 alkyl, C.sub.3-8 alkenyl, C.sub.3-7
cycloalkyl, (C.sub.3-7 cycloalkyl)C.sub.1-6 alkylene, (C.sub.2-15
heterocyclyl)C.sub.1-6 alkylene, or (phenyl) C.sub.1-6
alkylene;
[0030] W is --CN, --CHO, halogen, C.sub.1-8 heterocyclyl,
(C.sub.1-8 heterocyclyl)-O--, phenoxy, phenyl, (phenyl)C.sub.1-6
alkylene-O--, --C(.dbd.O)R.sub.x, --C(OH)R.sub.xR.sub.y,
--C.sub.1-8 alkyl, C.sub.1-8 cycloalkyl, or --NR.sub.xR.sub.y;
[0031] wherein each of R.sub.x and R.sub.y is independently
selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkanoyl, C.sub.1-8
heterocyclyl, and phenyl;
[0032] wherein each of the above alkyl, alkylene, alkenyl,
alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl
groups may each be independently and optionally substituted with
between 1 and 3 substituents selected from halo, amino, nitro,
hydroxyl, and C.sub.1-3 alkyl;
[0033] wherein substituents of Q can be further selected from
carboxamide, C.sub.2-6 alkyl, C.sub.1-8 heterocyclyl, N(C.sub.1-6
alkyl)(C.sub.1-8 heterocyclyl), NH(C.sub.1-8 heterocyclyl),
(C.sub.1-3 alkylene)(C.sub.1-8 heterocyclyl), O(C.sub.1-8
heterocyclyl), O(C.sub.1-6 alkyl), O(C.sub.3-6 cycloalkyl), phenyl,
(C.sub.1-3 alkylene)phenyl, N(C.sub.1-6 alkyl)(C.sub.1-3
alkylene)phenyl, and O(C.sub.1-3 alkylene)phenyl where each of
above heterocyclyl, phenyl, and alkyl groups may be optionally
substituted with from 1 to 3 substituents independently selected
from halogen, nitro, cyano, and C.sub.1-3 alkyl;
[0034] or a pharmaceutically acceptable salt, ester, or amide
thereof.
[0035] The invention also features a pharmaceutical composition
comprising a compound of the invention and a pharmaceutically
acceptable carrier; and methods of preparing or formulating such
compositions. A composition of the invention may further include
more than one compound of the invention, or a combination therapy
(combination formulation or administering a combination of
differently formulated active agents).
[0036] The invention also provides methods of treating certain
conditions and diseases, each of which methods includes
administering a therapeutically effective (or jointly effective)
amount of a compound or composition of the invention to a subject
in need of such treatment. The disclosed compounds are useful in
methods for treating or preventing neurologic disorders including
sleep/wake and arousal/vigilance disorders (e.g. insomnia and jet
lag), attention deficit hyperactivity disorders (ADHD), learning
and memory disorders, cognitive dysfunction, migraine, neurogenic
inflammation, dementia, mild cognitive impairment (pre-dementia),
Alzheimer's disease, epilepsy, narcolepsy, eating disorders,
obesity, motion sickness, vertigo, schizophrenia, substance abuse,
bipolar disorders, manic disorders and depression, as well as other
histamine H.sub.3 receptor mediated disorders such as upper airway
allergic response, asthma, itch, nasal congestion and allergic
rhinitis in a subject in need thereof. For example, the invention
features methods for preventing, inhibiting the progression of, or
treating upper airway allergic response, asthma, itch, nasal
congestion and allergic rhinitis.
[0037] In yet another embodiment, the disclosed compounds may be
used in a combination therapy method including administering a
jointly effective dose of an H.sub.3 antagonist and administering a
jointly effective dose of a histamine H.sub.1 antagonist, such as
loratidine (CLARITIN.TM.), desloratidine (CLARINEX.TM.),
fexofenadine (ALLEGRA.TM.) and cetirizine (ZYRTEC.TM.), for the
treatment of allergic rhinitis, nasal congestion and allergic
congestion.
[0038] In yet another embodiment, the disclosed compounds may be
used in a combination therapy method, including administering a
jointly effective dose of an H.sub.3 antagonist and administering a
jointly effective dose of a neurotransmitter re-uptake blocker,
such as a selective serotonin re-uptake inhibitor (SSRI) or a
non-selective serotonin, dopamine or norepinephrine re-uptake
inhibitor, including fluoxetine (PROZAC.TM.), sertraline
(ZOLOFT.TM.), paroxetine (PAXIL.TM.) and amitryptyline, for the
treatment of depression, mood disorders or schizophrenia.
[0039] Additional features and advantages of the invention will
become apparent from the detailed description and examples below,
and the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[0040] The present invention provides aryloxypiperidine derivatives
useful for the treatment of disorders and conditions modulated by a
histamine receptor.
[0041] A. Terms
[0042] Certain terms are defined below and by their usage
throughout this disclosure.
[0043] As used herein, "halogen" shall mean chlorine, bromine,
fluorine and iodine, or monovalent radicals thereof.
[0044] As used herein, the term "alkyl", whether used alone or as
part of a substituent group, shall include straight and branched
carbon chains. For example, alkyl radicals include methyl, ethyl,
propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and
the like. Unless otherwise noted, "lower" when used with alkyl
means a carbon chain composition of 1-4 carbon atoms. "Alkylene"
refers to a bivalent hydrocarbyl group, such as methylene
(CH.sub.2), ethylene (--CH.sub.2--CH.sub.2--) or propylene
(--CH.sub.2CH.sub.2CH.sub.2--).
[0045] As used herein, unless otherwise noted, "alkoxy" shall
denote an oxygen ether radical of the above described straight or
branched chain alkyl groups. For example, methoxy, ethoxy,
n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like.
[0046] As used herein, unless otherwise noted, "cycloalkyl" shall
denote a three- to eight-membered, saturated monocyclic carbocyclic
ring structure. Suitable examples include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
[0047] As used herein, unless otherwise noted, "cycloalkenyl" shall
denote a three- to eight-membered, partially unsaturated,
monocyclic, carbocyclic ring structure, wherein the ring structure
contains at least one double bond. Suitable examples include
cyclohexenyl, cyclopentenyl, cycloheptenyl, cyclooctenyl,
cyclohex-1,3-dienyl and the like.
[0048] As used herein, unless otherwise noted, "aryl" shall refer
to carbocyclic aromatic groups such as phenyl, naphthyl, and the
like. Divalent radicals include phenylene (--C.sub.6H.sub.4--)
which is preferably phen-1,4-diyl, but may also be
phen-1,3-diyl.
[0049] As used herein, unless otherwise noted, "aralkyl" shall mean
any alkyl group substituted with an aryl group such as phenyl,
naphthyl and the like. Examples of aralkyls include benzyl,
phenethyl, and phenylpropyl.
[0050] As used herein, unless otherwise noted, the terms
"heterocycle", "heterocyclyl" and "heterocyclo" shall denote any
five-, six-, or seven-membered monocyclic, nine or ten membered
bicyclic or thirteen or fourteen membered tricyclic ring structure
containing at least one heteroatom moiety selected from the group
consisting of N, O, SO, SO.sub.2, (C.dbd.O), and S, and preferably
N, O, or S, optionally containing one to four additional
heteroatoms in each ring. In some embodiments, the heterocyclyl
contains between 1 and 3 or between 1 and 2 additional heteroatoms.
Unless otherwise specified, a heterocyclyl may be saturated,
partially unsaturated, aromatic or partially aromatic. The
heterocyclyl group may be attached at any heteroatom or carbon atom
which results in the creation of a stable structure.
[0051] Exemplary monocyclic heterocyclic groups can include
pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl,
imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl,
isoxazolinyl, isoxazolyl, thiazaolyl, thiadiazolyl, thiazolidinyl,
isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl,
oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl,
2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl, azepinyl,
hexahydroazepinyl, 4-piperidinyl, pyridyl, N-oxo-pyridyl,
pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl,
tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl,
thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl
sulfone, 1,3-dixolane and tetrahydro-1,1-dioxothienyl, dioxanyl,
isothiazolidinyl, thietanyl, thiiranyl, triazinyl, triazolyl,
tetrazolyl, azetidinyl and the like.
[0052] For example, where Q is a non-aromatic nitrogen-containing
heterocyclyl, preferred values for Q include piperidyl,
piperazinyl, pyrrolinyl, pyrrolidinyl, morpholinyl, and N-(C1-6
alkyl) piperazinyl. These may be linked to the rest of the molecule
by a nitrogen or a carbon atom; in general, N-linked heterocyclyls
are preferred. Q can be substituted with between 1 and 3
substituents selected from pyridyl, pyrimidyl, furyl, thiofuryl,
imidazolyl, (imidazolyl)C.sub.1-6 alkylene, oxazolyl, thiazolyl,
2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl,
(tetrazolyl)C.sub.1-6 alkylene, tetrazolyl, (triazolyl)C.sub.1-6
alkylene, triazolyl, (pyrrolyl)C.sub.1-6 alkylene, and pyrrolyl.
Examples of substituted Q, wherein the substituent comprises a
heterocyclyl, include: 4-(4-chloropyridin-2-yl)amino-piperidi-
n-1-yl; 4-(4-chloropyrimidin-2-yl)amino-piperidin-1-yl;
2-([1,2,4]triazol-1-yl)methyl-morpholin-1-yl,
3-(pyrazin-2-yl)piperidin-1- -yl; 4-(pyrazol-1-yl)piperidin-1-yl;
4-(pyrimidin-2-yl)piperazin-1-yl;
4-(furan-2-yl)methylpiperazin-1-yl;
4-(thiophen-2-yl)methylpiperazin-1-yl- ;
4-(4-chloropyridin-2-yl)-[1,4]diazepan-1-yl; and
5-(isoxazol-5-yl)-2,5-d- iaza-bicyclo[2.2.1]heptan-2-yl.
[0053] Exemplary bicyclic heterocyclic groups include
benzthiazolyl, benzoxazolyl, benzoxazinyl, benzothienyl,
quinuclidinyl, quinolinyl, quinolinyl-N-oxide,
tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl,
benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl,
cinnolinyl, quinoxalinyl, indazolyl, pyrrolopridyl, furopyridinyl
(such as furo[2,3-c]pyridinyl, furo[3,1-b]pyridinyl), or
furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such
as 3,4-dihydro-4-oxo-quinazolinyl), tetrahydroquinolinyl (such as
1,2,3,4-tetrahydroquinolinyl), tetrahydroisoquinolinyl(such as
1,2,3,4-tetrahydroisoquiunolinyl), benzisothiazolyl,
benzisoxazolyl, benzodiazinyl, benzofurazanyl, benzothiopyranyl,
benzotriazolyl, benzpyrazolyl, dihydrobenzofuryl,
dihydrobenzothienyl, dihydrobenzothiopyranyl,
dihydrobenzothiopyranyl sulfone, dihydrobenzopyranyl, indolinyl,
isoindolyl, tetrahydroindoazolyl (such as
4,5,6,7-tetrahydroindazolyl), isochromanyl, isoindolinyl,
naphthyridinyl, phthalazinyl, piperonyl, purinyl, pyridopyridyl,
quinazolinyl, tetrahydroquinolinyl, thienofuryl, thienopyridyl,
thienothienyl, 3
[0054] Exemplary tricyclic heterocylclic groups include acridinyl,
phenoxazinyl, phenazinyl, phenothiazinyl, carbozolyl, perminidinyl,
phenanthrolinyl, carbolinyl, naphthothienyl, thianthrenyl, and the
like.
[0055] Preferred heterocyclyl groups include morpholinyl,
piperidinyl, piperazinyl, pyrrolidinyl, pyrimidinyl, pyridyl,
pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, acridinyl, azepinyl,
hexahydroazepinyl, azetidinyl, indolyl, isoindolyl, thiazolyl,
thiadiazolyl, quinolinyl, isoquinolinyl,
1,2,3,4-tetrahydroquinolinyl, 1,3,4-trihydroisoquinolinyl,
4,5,6,7-tetrahydroindadolyl, benzoxazinyl, benzoaxzolyl,
benzthiazolyl, benzimidazolyl, tetrazolyl, oxadiazolyl, 4
[0056] As used herein, unless otherwise noted, the term
"heterocyclyl-alkyl" or "heterocyclyl-alkylene" shall denote any
alkyl group substituted with a heterocyclyl group, wherein the
heterocycly-alkyl group is bound through the alkyl portion to the
central part of the molecule. Suitable examples of
heterocyclyl-alkyl groups include, but are not limited to
piperidinylmethyl, pyrrolidinylmethyl, piperidinylethyl,
piperazinylmethyl, pyrrolylbutyl, piperidinylisobutyl,
pyridylmethyl, pyrimidylethyl, and the like.
[0057] When a particular group is "substituted" (e.g., alkyl,
alkylene, cycloalkyl, aryl, heterocyclyl, heteroaryl), that group
may have one or more substituents, preferably from one to five
substituents, more preferably from one to three substituents, most
preferably from one to two substituents, independently selected
from the list of substituents.
[0058] It is intended that the definition of any substituent or
variable at a particular location in a molecule be independent of
its definitions elsewhere in that molecule. It is understood that
substituents and substitution patterns on the compounds of this
invention can be selected by one of ordinary skill in the art to
provide compounds that are chemically stable and that can be
readily synthesized by techniques known in the art as well as those
methods set forth herein.
[0059] Under standard nomenclature used throughout this disclosure,
the terminal portion of the designated side chain is described
first, followed by the adjacent functionality toward the point of
attachment. Thus, for example, a "phenyl(alkyl)amido(alkyl)"
substituent refers to a group of the formula 5
[0060] The term "subject" as used herein, refers to an animal,
preferably a mammal, most preferably a human, who has been the
object of treatment, observation or experiment.
[0061] The term "therapeutically effective amount" as used herein,
means that amount of active compound or pharmaceutical agent that
elicits the biological or medicinal response in a tissue system,
animal or human that is being sought by a researcher, veterinarian,
medical doctor or other clinician, which includes prevention,
inhibition of onset, or alleviation of the symptoms of the disease
or disorder being treated.
[0062] As used herein, the term "composition" is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combinations of the specified ingredients in
the specified amounts.
[0063] Abbreviations used in the specification, particularly in the
Schemes and Examples, are as follows:
1 DBAD = di-tert-butyl azodicarboxylate DCE = 1,2-dichloroethane
DCM = dichloromethane DEAD = diethyl azodicarboxylate DMA =
N,N-dimethylacetamide DMAP = 4-N,N-dimethylamino- pyridine DME =
1,2-dimethoxyethane DMF = dimethylformamide DMSO =
dimethylsulfoxide RT = room temperature TEA = triethylamine TFA =
trifluoroacetic acid THF = tetrahydrofuran
[0064] The next section describes the compounds provided by the
invention in more detail.
[0065] B. Compounds
[0066] The invention features compounds of formula (I) as described
in the above Summary section and, for example, in the claims.
Preferred compounds include those wherein:
[0067] (a) R.sub.5 is C.sub.1-5 alkyl, C.sub.3-4 alkenyl, C.sub.3-6
cycloalkyl, (C.sub.3-6 cycloalkyl) C.sub.1 alkylene,
(phenyl)C.sub.1-3 alkylene, or (phenyl)C.sub.3-4 alkenylene;
[0068] (b) R.sub.5 is branched C.sub.3-5 alkyl, C.sub.3-6
cycloalkyl, and (C.sub.3-6 cycloalkyl )C.sub.1 alkylene;
[0069] (c) one of R.sub.2 and R.sub.3 is G;
[0070] (d) R.sub.2 is G;
[0071] (e) R.sub.3 is G;
[0072] (f) L.sub.1 is C.sub.2-3 alkylene;
[0073] (g) L.sub.2 is C.sub.1-6 alkylene, (C.sub.1-5
heteroaryl)C.sub.1-6 alkylene, or -phenyl-C.sub.1-6 alkylene;
[0074] (h) L.sub.2 is methylene;
[0075] (i) L.sub.3 is ethylene, vinylene, ethynylene, and
phenylene;
[0076] (j) Q is a non-aromatic nitrogen-containing C.sub.2-5
heterocyclyl;
[0077] (k) Q is selected from piperidyl, N--(C.sub.1-6
alkyl)piperazinyl, piperazinyl, pyrrolinyl, pyrrolidinyl, and
morpholinyl;
[0078] (l) Q is N-morpholinyl or N-piperidinyl, optionally
substituted with between 1 and 3 substituents selected from
hydroxyl, carboxamide, C.sub.1-6 alkyl, C.sub.1-8 heterocyclyl,
N(C.sub.1-6 alkyl)(C.sub.1-8 heterocyclyl), NH(C.sub.1-8
heterocyclyl), (C.sub.1-3 alkylene)(C.sub.1-8 heterocyclyl),
O(C.sub.1-8 heterocyclyl), O(C.sub.1-6 alkyl), O(C.sub.3-6
cycloalkyl), phenyl, (C.sub.1-3 alkylene)phenyl, N(C.sub.1-6
alkyl)(C.sub.1-3 alkylene) phenyl, and O(C.sub.1-3 alkylene)phenyl
where each of above heterocyclyl, phenyl, and alkyl groups may be
optionally substituted with from 1 to 3 substituents independently
selected from halogen, nitro, cyano, and C.sub.1-3 alkyl;
[0079] (m) Q is substituted with a substituent comprising a
C.sub.1-6 heterocyclyl group selected from: pyridyl, pyrimidyl,
furyl, thiofuryl, imidazolyl, (C.sub.1-6 alkyl) imidazolyl,
oxazolyl, thiazolyl, 2,3-dihydro-indolyl, benzimidazolyl,
2-oxobenzimidazolyl, (C.sub.1-6 alkyl) tetrazolyl, tetrazolyl,
(C.sub.1-6 alkyl) triazolyl, triazolyl, (C.sub.1-6 alkyl) pyrrolyl,
and pyrrolyl;
[0080] (n) Q is a substituted or unsubstituted N-morpholinyl;
[0081] (o) Q is NR.sub.8R.sub.9 wherein each of R.sub.8 or R.sub.9
is independently selected from hydrogen, C.sub.1-8 alkyl, C.sub.3-8
alkenyl, C.sub.3-7 cycloalkyl, (C.sub.3-7 cycloalkyl)C.sub.1-6
alkylene, C.sub.2-5 heterocyclyl, phenyl, (C.sub.2-5
heterocyclyl)C.sub.1-6 alkylene, and (phenyl) C.sub.1-6
alkylene;
[0082] (p) one of R.sub.8 and R.sub.9 is hydrogen;
[0083] (q) R.sub.8 is H and R.sub.9 is phenyl or aromatic C.sub.1-8
heterocyclyl optionally substituted with 1-3 substituents selected
from halo, nitro, cyano, and C.sub.1-3 alkyl;
[0084] (r) R.sub.9 is phenyl, pyridyl, pyrimidyl, furyl, thiofuryl,
imidazolyl, (C.sub.1-6 alkyl) imidazolyl, oxazolyl, thiazolyl,
2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl,
(C.sub.1-6 alkyl) tetrazolyl, tetrazolyl, (C.sub.1-6 alkyl)
triazolyl, triazolyl, (C.sub.1-6 alkyl) pyrrolyl, and pyrrolyl;
[0085] (s) R.sub.5 is C.sub.1-5 alkyl, C.sub.3-4 alkenyl, C.sub.3-6
cycloalkyl, (C.sub.3-6 cycloalkyl) C.sub.1alkylene,
(phenyl)C.sub.1-3 alkylene, or (phenyl)C.sub.3-4 alkenylene;
[0086] (t) n is 0 or 1;
[0087] (u) n is 0;
[0088] (v) G is selected from:
[0089] (1) formula (i) wherein L.sub.4 and L.sub.5 are
independently selected from C.sub.2-3 alkylene,
[0090] (2) formula (iii) wherein L.sub.6 is C.sub.2-3 alkylene and
L.sub.7 is C.sub.2-3 alkylene or absent,
[0091] (3) L.sub.2Q wherein L.sub.2 is C.sub.1-6 alkylene, phenyl
C.sub.1-4 alkylene, or (aromatic C.sub.1-5 heterocyclyl)C.sub.1-4
alkylene, and
[0092] (4) OL.sub.1Q wherein L.sub.1 is C.sub.2-3 alkylene;
[0093] (w) G is selected from:
[0094] (1) formula (i) wherein L.sub.4 and L.sub.5 are each C.sub.2
alkylene,
[0095] (2) formula (iii) wherein each of L.sub.6 and L.sub.7 is
C.sub.2 alkylene, and
[0096] (3) L.sub.2Q wherein L.sub.2 is methylene;
[0097] (x) wherein G is L.sub.2Q;
[0098] (y) R.sub.10 is H, branched C.sub.3-6 alkyl, or benzyl;
[0099] (z) R.sub.10 is isopropyl or benzyl;
[0100] (aa) Q is a non-aromatic C.sub.2-5 heterocyclyl;
[0101] (bb) Q is selected from piperidyl, N-(C.sub.1-6
alkyl)piperazinyl, piperazinyl, pyrrolinyl, pyrrolidinyl, and
morpholinyl;
[0102] (cc) R.sub.5 is C.sub.1-5 alkyl, C.sub.3-4 alkenyl,
C.sub.3-6 cycloalkyl, (C.sub.3-6 cycloalkyl) C.sub.1alkylene,
(phenyl)C.sub.1-3 alkylene, or (phenyl)C.sub.3-4 alkenylene;
[0103] (dd) R.sub.7 is hydroxyl, halo, or absent where one of
L.sub.6 and L.sub.7 provides a double bond to the carbon atom to
which R.sub.6 and R.sub.7are attached;
[0104] (ee) one of R.sub.2 and R.sub.3 is G;
[0105] (ff) one of R.sub.2 and R.sub.3 is W, and W is a
heterocyclyl selected from: pyridyl, pyrimidyl, furyl, thiofuryl,
imidazolyl, oxazolyl, thiazolyl, 2,3-dihydro-indolyl,
benzimidazolyl, tetrazolyl, triazolyl, and pyrrolyl;
[0106] (gg) R.sub.5 is branched C.sub.3-5 alkyl;
[0107] (hh) R.sub.5 is isopropyl or cyclopentyl; or
[0108] (ii) Combinations of the above.
[0109] Preferred compounds of the invention include:
4-(4-Imidazol-1-yl-phenoxy)-1-isopropyl-piperidine,
4-(4-Imidazol-1-yl-phenoxy)-1-isobutyl-piperidine,
1-Isopropyl-4-(4-pyrrol-1-yl-phenoxy)-piperidine,
5-Chloro-2-[4-(1-isopro-
pyl-piperidin-4-yloxy)-phenyl]-1H-benzoimidazole, and more
preferably, 4-(4-Imidazol-1-yl-phenoxy)-1-isopropyl-piperidine,
4-(4-Imidazol-1-yl-phenoxy)-1-isobutyl-piperidine, and
5-Chloro-2-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-1H-benzoimidazole.
[0110] The invention also features:
[4-(1-Isopropyl-piperidin-4-yloxy)-phe- nyl]-phenyl-methanone,
4-(Biphenyl-4-yloxy)-1-isopropyl-piperidine,
4-(4-Benzyloxy-phenoxy)-1-isopropyl-piperidine,
1-Isopropyl-4-(4-phenoxy-- phenoxy)-piperidine,
4-(4-Benzyl-phenoxy)-1-isopropyl-piperidine,
[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-phenyl-methanol,
N-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-acetamide,
4-(4-Cyclopentyl-phenoxy)-1-isopropyl-piperidine,
4-(1-Cyclopentyl-piperi- din-4-yloxy)-benzonitrile,
4-(1-Cyclobutyl-piperidin-4-yloxy)-benzonitrile- ,
4-(1-sec-Butyl-piperidin-4-yloxy)-benzonitrile,
4-(1-Isopropyl-piperidin- -4-yloxy)-benzaldehyde,
4-(1-Cyclohexyl-piperidin-4-yloxy)-benzonitrile,
4-(1-Isopropyl-piperidin-4-yloxy)-benzonitrile,
4-(1-Cyclopropylmethyl-pi- peridin-4-yloxy)-benzonitrile,
4-(1-Isobutyl-piperidin-4-yloxy)-benzonitri- le, and
4-(1-Propyl-piperidin-4-yloxy)-benzonitrile.
[0111] The invention also provides more preferred compounds such
as: 4-(Biphenyl-4-yloxy)-1-isopropyl-piperidine,
4-(4-Benzyloxy-phenoxy)-1-is- opropyl-piperidine,
4-(4-Benzyl-phenoxy)-1-isopropyl-piperidine,
1-Isopropyl-4-(4-phenoxy-phenoxy)-piperidine, and
N-[4-(1-Isopropyl-piper- idin-4-yloxy)-phenyl]-acetamide.
[0112] Preferred compounds also include those such as: (A)
1-Isopropyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-piperazine,
and 1-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-piperazine
1-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-piperazine; and (B)
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidine,
4-[4-(1-sec-Butyl-piperidin -4-yloxy)-benzyl]-morpholine,
1-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-N-Isopropyl-4-{4-[5-(1-isopropyl-piperidin-4-ylsulfanyl)-tetrazol-1-yl]-
-phenoxy}-piperidine,
{1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperi-
din-4-yl}-methanol,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl--
[1,4]diazepane,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidin-4-ol,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-methyl-(1-methyl-piperidin-4-y-
l)-amine,
1-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-4-benzyl-piperidine- ,
N-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-N,N',N'-trimethyl-ethane-1,-
2-diamine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-piperazin- e,
Cyclohexyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
Butyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
4-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-Isopropyl-4-(4-pyrrolidin-1-ylmethyl-phenoxy)-piperidine,
Diethyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine,
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-4-phenyl-piperazine,
1-Benzyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperazine,
4-[4-(4-Benzylidene-piperidin-1-ylmethyl)-phenoxy]-1-isopropyl-piperidine-
, 4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-dimethyl-amine,
4-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-morpholine,
4-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-morpholine,
4-[4-(1-Propyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Benzyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Cyclohexylmethyl-piperidin-4-yloxy)-benzyl]-piperidine, and
4-[4-(4-Piperidin-1-ylmethyl-phenoxy)-piperidin-1-yl]-butan-2-one.
[0113] Highly preferred compounds include:
1-[4-(1-Isopropyl-piperidin-4-y- loxy)-benzyl]-piperidine,
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-mor- pholine,
1-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-N-Isopropyl-4-{4-[5-(1-isopropyl-piperidin-4-ylsulfanyl)-tetrazol-1-yl]-
-phenoxy}-piperidine,
{1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperi-
din-4-yl}-methanol,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl--
[1,4]diazepane,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane,
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidin-4-ol,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-methyl-(1-methyl-piperidin-4-y-
l)-amine,
1-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-4-benzyl-piperidine- ,
N-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-N,N',N'-trimethyl-ethane-1,-
2-diamine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-piperazin- e,
Cyclohexyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
Butyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine,
4-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-Isopropyl-4-(4-pyrrolidin-1-ylmethyl-phenoxy)-piperidine,
Diethyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine,
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine,
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-phenyl-piperazine,
1-Benzyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperazine,
4-[4-(4-Benzylidene-piperidin-1-ylmethyl)-phenoxy]-1-isopropyl-piperidine-
, 4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-dimethyl-amine,
4-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-morpholine, and
4-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-morpholine.
[0114] Examples of highly preferred compounds also include:
Cyclopropyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-(5-methyl-pyridin-2-yl)-amine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-pyridin-2-yl-amine,
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-phenyl-amine, and
(5-Chloro-pyridin-2-yl)-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine.
[0115] The invention also provides compounds that are useful as
synthetic intermediates of the compounds of the invention. Such
compounds, which themselves may or may not have pharmaceutical
activity, include those provided in the Schemes and synthetic
examples.
[0116] The invention also contemplates compounds
isotopically-labelled to be detectable by positron emission
tomography (PET) or single-photon emission computed tomography
(SPECT) useful for studying H.sub.3-mediated disorders.
[0117] During any of the processes for preparation of the compounds
of the present invention, it may be necessary and/or desirable to
protect sensitive or reactive groups on any of the molecules
concerned. In addition, compounds of the invention may be modified
by using protecting groups; such compounds, precursors, or prodrugs
are also within the scope of the invention. This may be achieved by
means of conventional protecting groups, such as those described in
"Protective Groups in Organic Chemistry", ed. J. F. W. McOmie,
Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts,
"Protective Groups in Organic Synthesis", 3.sup.rd ed., John Wiley
& Sons, 1999. The protecting groups may be removed at a
convenient subsequent stage using methods known from the art.
[0118] HYDROXYL PROTECTING GROUPS
[0119] Protection for the hydroxyl group includes methyl ethers,
substituted methyl ethers, substituted ethyl ethers, substitute
benzyl ethers, and silyl ethers.
[0120] Substituted Methyl Ethers
[0121] Examples of substituted methyl ethers include
methyoxymethyl, methylthiomethyl, t-butylthiomethyl,
(phenyidimethylsilyl)methoxymethyl, benzyloxymethyl,
p-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, guaiacolmethyl,
t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl,
2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl,
bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl,
tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl,
1-methoxycyclohexyl, 4-methoxytetrahydropyranyl,
4-methoxytetrahydrothiop- yranyl, 4-methoxytetrahydrothiopyranyl
S,S-dioxido, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl,
1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl and
2,3,3a,4,5,6,7,7a-octahydro--
7,8,8-trimethyl-4,7-methanobenzofuran-2-yl.
[0122] Substituted Ethyl Ethers
[0123] Examples of substituted ethyl ethers include 1-ethoxyethyl,
1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl,
1-methyl-1-benzyloxyeth- yl, 1-methyl-1-benzyloxy-2-fluoroethyl,
2,2,2-trichloroethyl, 2-trimethylsilylethyl,
2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl,
p-methoxyphenyl, 2,4-dinitrophenyl, and benzyl.
[0124] Substituted Benzyl Ethers
[0125] Examples of substituted benzyl ethers include
p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl,
p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-
and 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl,
p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl,
.alpha.-naphthyldiphenylmethyl, p-methoxyphenyidiphenylmethyl,
di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl,
4-(4'-bromophenacyloxy)phenyldiphenylmethyl,
4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl,
4,4',4"-tris(levulinoyloxyphenyl)methyl,
4,4',4"-tris(benzoyloxyphenyl)me- thyl,
3-(Imidazol-1-ylmethyl)bis(4',4"-dimethoxyphenyl)methyl,
1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl,
9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl,
1,3-benzodithiolan-2-yl, and benzisothiazolyl S,S-dioxido.
[0126] Silyl Ethers
[0127] Examples of silyl ethers include trimethylsilyl,
triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl,
diethylisopropylsilyl, dimethylthexylsilyl, t-butyldimethylsilyl,
t-butyldiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl,
triphenylsilyl, diphenylmethylsilyl, and
t-butylmethoxyphenylsilyl.
[0128] Esters
[0129] In addition to ethers, a hydroxyl group may be protected as
an ester. Examples of esters include formate, benzoylformate,
acetate, chloroacetate, dichloroacetate, trichloroacetate,
trifluoroacetate, methoxyacetate, triphenylmethoxyacetate,
phenoxyacetate, p-chlorophenoxyacetate, p-P-phenylacetate,
3-phenylpropionate, 4-oxopentanoate(levulinate),
4,4-(ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate,
4-methoxycrotonate, benzoate, p-phenylbenzoate,
2,4,6-trimethylbenzoate(mesitoate)
[0130] Carbonates
[0131] Examples of carbonates include methyl, 9-fluorenylmethyl,
ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl,
2-(phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl,
vinyl, allyl, p-nitrophenyl, benzyl, p-methoxybenzyl,
3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, S-benzyl
thiocarbonate, 4-ethoxy-1-naphthyl, and methyl dithiocarbonate.
[0132] Assisted Cleavage
[0133] Examples of assisted cleavage include 2-iodobenzoate,
4-azidobutyrate, 4-nitro-4-methylpentanoate,
o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate,
2-(methylthiomethoxy)ethyl carbonate,
4-(methylthiomethoxy)butyrate, and
2-(methylthiomethoxymethyl)benzoate.
[0134] Miscellaneous Esters
[0135] Examples of miscellaneous esters include
2,6-dichloro-4-methylpheno- xyacetate,
2,6-dichloro-4-(1,1,3,3-tetramethyl butyl)phenoxyacetate,
2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate,
isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate(tigloate),
o-(methoxycarbonyl)benzoate, p-P-benzoate, .alpha.-naphthoate,
nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate,
N-phenylcarbamate, borate, dimethylphosphinothioyl, and
2,4-dinitrophenylsulfenate
[0136] Sulfonates
[0137] Examples of sulfonates include sulfate,
methanesulfonate(mesylate), benzylsulfonate, and tosylate.
[0138] PROTECTION FOR 1,2- AND 1,3-DIOLS
[0139] Cyclic Acetals and Ketals
[0140] Examples of cyclic acetals and ketals include methylene,
ethylidene, 1-t-butylethylidene, 1-phenylethylidene,
(4-methoxyphenyl)ethylidene, 2,2,2-trichloroethylidene, acetonide
(isopropylidene), cyclopentylidene, cyclohexylidene,
cycloheptylidene, benzylidene, p-methoxybenzylidene,
2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene, and
2-nitrobenzylidene.
[0141] Cyclic Ortho Esters
[0142] Examples of cyclic ortho esters include methoxymethylene,
ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene,
1-ethoxyethylidine, 1,2-dimethoxyethylidene,
.alpha.-methoxybenzylidene, 1-(N,N-dimethylamino)ethylidene
derivative, .alpha.-(N,N-dimethylamino)be- nzylidene derivative,
and 2-oxacyclopentylidene.
[0143] Silyl Derivatives
[0144] Examples of silyl derivatives include di-t-butylsilylene
group, and 1,3-(1,1,3,3-tetraisopropyld isiloxanylidene)
derivative.
[0145] AMINO PROTECTING GROUPS
[0146] Protection for the amino group includes carbamates, amides,
and special--NH protective groups.
[0147] Examples of carbamates include methyl and ethyl carbamates,
substituted ethyl carbamates, assisted cleavage carbamates,
photolytic cleavage carbamates, urea-type derivatives, and
miscellaneous carbamates.
[0148] Carbamates
[0149] Examples of methyl and ethyl carbamates include methyl and
ethyl, 9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl,
9-(2,7-dibromo)fluorenylme- thyl,
2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]me-
thyl, and 4-methoxyphenacyl.
[0150] Substituted Ethyl
[0151] Examples of substituted ethyl carbamates include
2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl,
1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl,
1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl,
1-methyl-1-(4-biphenylyl)ethyl,
1-(3,5-di-t-butylphenyl)-1-methylethyl, 2-(2'- and
4'-pyridyl)ethyl, 2-(N,N-dicyclohexylcarboxamido)ethyl, t-butyl,
1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl,
4-nitrocinnamyl, 8-quinolyl, N-hydroxypiperidinyl, alkyldithio,
benzyl, p-methoxybenzyl, p-nitrobenzyl, p-bromobenzyl,
p-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl,
9-anthrylmethyl and diphenylmethyl.
[0152] Assisted Cleavage
[0153] Examples of assisted cleavage include 2-methylthioethyl,
2-methylsulfonylethyl, 2-(p-toluenesulfonyl)ethyl,
[2-(1,3-dithianyl)]methyl, 4-methylthiophenyl,
2,4-dimethylthiophenyl, 2-phosphonioethyl,
2-triphenylphosphonioisopropyl, 1,1-dimethyl-2-cyanoethyl,
m-chloro-p-acyloxybenzyl, p-(dihydroxyboryl)benzyl,
5-benzisoxazolylmethyl, and
2-(trifluoromethyl)-6-chromonylmethyl.
[0154] Photolytic Cleavage
[0155] Examples of photolytic cleavage include m-nitrophenyl,
3,5-dimethoxybenzyl, o-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl,
and phenyl(o-nitrophenyl)methyl.
[0156] Urea-Type Derivatives
[0157] Examples of urea-type derivatives include
phenothiazinyl-(10)-carbo- nyl derivative,
N'-p-toluenesulfonylaminocarbonyl, and
N'-phenylaminothiocarbonyl.
[0158] Miscellaneous Carbamates
[0159] Examples of miscellaneous carbamates include t-amyl,
S-benzyl thiocarbamate, p-cyanobenzyl, cyclobutyl, cyclohexyl,
cyclopentyl, cyclopropylmethyl, p-decyloxybenzyl,
diisopropylmethyl, 2,2-dimethoxycarbonylvinyl,
o-(N,N-dimethylcarboxamido)benzyl,
1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl,
1,1-dimethylpropynyl, di(2-pyridyl)methyl, 2-furanylmethyl,
2-iodoethyl, isobornyl, isobutyl, isonicotinyl,
p-(p'-methoxyphenylazo)benzyl, 1-methylcyclobutyl,
1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl,
1-methyl-1-(3,5-dimetho- xyphenyl)ethyl,
1-methyl-1-(p-phenylazophenyl)ethyl, 1-methyl-1-phenylethyl,
1-methyl-1-(4-pyridyl)ethyl, phenyl, p-(phenylazo)benzyl,
2,4,6-tri-t-butylphenyl, 4-(trimethylammonium)benzyl- , and
2,4,6-trimethylbenzyl.
[0160] Examples of amides include:
[0161] Amides
[0162] N-formyl, N-acetyl, N-chloroacetyl, N-trichloroacetyl,
N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl,
N-picolinoyl, N-3-pyridylcarboxamide, N-benzoylphenylalanyl
derivative, N-benzoyl, N-p-phenylbenzoyl.
[0163] Assisted Cleavage
[0164] N-o-nitrophenylacetyl, N-o-nitrophenoxyacetyl,
N-acetoacetyl, (N'-dithiobenzyloxycarbonylamino)acetyl,
N-3-(p-hydroxyphenyl)propionyl, N-3-(o-nitrophenyl)propionyl,
N-2-methyl-2-(o-nitrophenoxy)propionyl,
N-2-methyl-2-(o-phenylazophenoxy)propionyl, N-4-chlorobutyryl,
N-3-methyl-3-nitrobutyryl, N-o-nitrocinnamoyl, N-acetylmethionine
derivative, N-o-nitrobenzoyl, N-o-(benzoyloxymethyl)benzoyl, and
4,5-diphenyl-3-oxazolin-2-one.
[0165] Cyclic Imide Derivatives
[0166] N-phthalimide, N-dithiasuccinoyl, N-2,3-diphenylmaleoyl,
N-2,5-dimethylpyrrolyl, N-1,1,4,4-tetramethyidisilylazacyclopentane
adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one,
5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, and
1-substituted 3,5-dinitro-4-pyridonyl.
[0167] SPECIAL--NH PROTECTIVE GROUPS
[0168] Examples of special NH protective groups include:
[0169] N-Alkyl and N-Aryl Amines
[0170] N-methyl, N-allyl, N-[2-(trimethylsilyl)ethoxy]methyl,
N-3-acetoxypropyl, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl),
quaternary ammonium salts, N-benzyl, N-4-methoxybenzyl,
N-di(4-methoxyphenyl)methyl, N-5-dibenzosuberyl, N-triphenylmethyl,
N-(4-methoxyphenyl)diphenylmethyl, N-9-phenylfluorenyl,
N-2,7-dichloro-9-fluorenylmethylene, N-ferrocenylmethyl, and
N-2-picolylamine N'-oxide.
[0171] Imine Derivatives
[0172] N-1,1-dimethylthiomethylene, N-benzylidene,
N-p-methoxybenzylidene, N-diphenylmethylene,
N-[(2-pyridyl)mesityl]methylene, and
N-(N',N'-dimethylaminomethylene).
[0173] PROTECTION FOR THE CARBONYL GROUP
[0174] Acyclic Acetals and Ketals
[0175] Examples of acyclic acetals and ketals include dimethyl,
bis(2,2,2-trichloroethyl), dibenzyl, bis(2-nitrobenzyl) and
diacetyl.
[0176] Cyclic Acetals and Ketals
[0177] Examples of cyclic acetals and ketals include 1,3-dioxanes,
5-methylene-1,3-dioxane, 5,5-dibromo-1,3-dioxane,
5-(2-pyridyl)-1,3-dioxa- ne, 1,3-dioxolanes,
4-bromomethyl-1,3-dioxolane, 4-(3-butenyl)-1,3-dioxola- ne,
4-phenyl-1,3-dioxolane, 4-(2-nitrophenyl)-1,3-dioxolane,
4,5-dimethoxymethyl-1,3-dioxolane, O,O'-phenylenedioxy and
1,5-dihydro-3H-2,4-benzodioxepin.
[0178] Acyclic Dithio Acetals and Ketals
[0179] Examples of acyclic dithio acetals and ketals include
S,S'-dimethyl, S,S'-diethyl, S,S'-dipropyl, S,S'-dibutyl,
S,S'-dipentyl, S,S'-diphenyl, S,S'-dibenzyl and S,S'-diacetyl.
[0180] Cyclic Dithio Acetals and Ketals
[0181] Examples of cyclic dithio acetals and ketals include
1,3-dithiane, 1,3-dithiolane and
1,5-dihydro-3H-2,4-benzodithiepin.
[0182] Acyclic Monothio Acetals and Ketals
[0183] Examples of acyclic monothio acetals and ketals include
O-trimethylsilyl-S-alkyl, O-methyl-S-alkyl or -S-phenyl and
O-methyl-S-2-(methylthio)ethyl.
[0184] Cyclic Monothio Acetals and Ketals
[0185] Examples of cyclic monothio acetals and ketals include
1,3-oxathiolanes.
[0186] MISCELLANEOUS DERIVATIVES
[0187] O-Substituted Cyanohydrins
[0188] Examples of O-substituted cyanohydrins include O-acetyl,
O-trimethylsilyl, O-1-ethoxyethyl and O-tetrahydropyranyl.
[0189] Substituted Hydrazones
[0190] Examples of substituted hydrazones include N,N-dimethyl and
2,4-dinitrophenyl.
[0191] Oxime Derivatives
[0192] Examples of oxime derivatives include O-methyl, O-benzyl and
O-phenylthiomethyl.
[0193] Imines
[0194] Substituted Methylene Derivatives, Cyclic Derivatives
[0195] Examples of substituted methylene and cyclic derivatives
include oxazolidines, 1-methyl-2-(1'-hydroxyalkyl)imidazoles,
N,N'-dimethylimidazolidines, 2,3-dihydro-1,3-benzothiazoles,
diethylamine adducts, and methylaluminum
bis(2,6-di-t-butyl-4-methylphenoxide)(MAD)com- plex.
[0196] MONOPROTECTION OF DICARBONYL COMPOUNDS
[0197] Selective Protection Of .alpha.-and .beta.-Diketones
[0198] Examples of selective protection of .alpha.-and
.beta.-diketones include enamines, enol acetates, enol ethers,
methyl, ethyl, i-butyl, piperidinyl, morpholinyl,
4-methyl-1,3-dioxolanyl, pyrrolidinyl, benzyl, S-butyl, and
trimethylsilyl.
[0199] Cyclic Ketals, Monothio and Dithio Ketals
[0200] Examples of cyclic ketals, monothio and dithio ketals
include bismethylenedioxy derivatives and
tetramethylbismethylenedioxy derivatives.
[0201] PROTECTION FOR THE CARBOXYL GROUP
[0202] Esters
[0203] Substituted Methyl Esters
[0204] Examples of substituted methyl esters include
9-fluorenylmethyl, methoxymethyl, methylthiomethyl,
tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl,
2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, phenacyl,
p-bromophenacyl, .alpha.-methylphenacyl, p-methoxyphenacyl,
carboxamidomethyl, and N-phthalimidomethyl.
[0205] 2-Substituted Ethyl Esters
[0206] Examples of 2-substituted ethyl esters include
2,2,2-trichloroethyl,
[0207] 2-haloethyl, .omega.-chloroalkyl, 2-(trimethylsilyl)ethyl,
2-methylthioethyl, 1,3-dithianyl-2-methyl,
2-(p-nitrophenylsulfenyl)ethyl- , 2-(p-toluenesulfonyl)ethyl,
[0208] 2-(2'-pyridyl)ethyl, 2-(diphenylphosphino)ethyl,
1-methyl-1-phenylethyl, t-butyl, cyclopentyl, cyclohexyl, allyl,
3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl,
.alpha.-methylcinnamyl, phenyl, p-(methylmercapto)phenyl and
benzyl.
[0209] Substituted Benzyl Esters
[0210] Examples of substituted benzyl esters include
triphenylmethyl, diphenylmethyl, bis(o-nitrophenyl)methyl,
9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-dibenzosuberyl,
1-pyrenylmethyl, 2-(trifluoromethyl)-6-chromylmethyl,
2,4,6-trimethylbenzyl, p-bromobenzyl, o-nitrobenzyl, p-nitrobenzyl,
p-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl,
4-sulfobenzyl, piperonyl, 4-picolyl and p-P-benzyl.
[0211] Silyl Esters
[0212] Examples of silyl esters include trimethylsilyl,
triethylsilyl, t-butyidimethylsilyl, i-propyidimethylsilyl,
phenyldimethylsilyl and di-t-butylmethylsilyl.
[0213] Activated Esters
[0214] Examples of activated esters include thiols.
[0215] Miscellaneous Derivatives
[0216] Examples of miscellaneous derivatives include oxazoles,
2-alkyl-1,3-oxazolines, 4-alkyl-5-oxo-1,3-oxazolidines,
5-alkyl-4-oxo-1,3-dioxolanes, ortho esters, phenyl group and
pentaaminocobalt(III) complex.
[0217] Stannyl Esters
[0218] Examples of stannyl esters include triethylstannyl and
tri-n-butylstannyl.
[0219] AMIDES AND HYDRAZIDES
[0220] Amides
[0221] Examples of amides include N,N-dimethyl, pyrrolidinyl,
piperidinyl, 5,6-dihydrophenanthridinyl, o-nitroanilides,
N-7-nitroindolyl, N-8-Nitro-1,2,3,4-tetrahydroquinolyl, and
p-P-benzenesulfonamides.
[0222] Hydrazides
[0223] Examples of hydrazides include N-phenyl and
N,N'-diisopropyl.
[0224] The compounds of the invention can be prepared according to
the methods described in the next section.
[0225] Synthesis
[0226] The compounds of the invention can be prepared according to
traditional synthetic organic methods and matrix or combinatorial
chemistry methods, as shown in Schemes 1-10 below and in Examples
1-86. A person of ordinary skill will be aware of variations and
adaptations of the schemes and examples provided to achieve the
compounds of the invention.
[0227] Throughout the schemes when the reacting functionality is
located at R.sub.3, one skilled in the art will recognize that the
choice of R.sub.3 is illustrative only and that the reacting
functionality could also be located at R.sub.1 and R.sub.2
also.
[0228] Compounds of formula (I) may be prepared according to the
processes outlined in Scheme 1. 6
[0229] A compound of formula (I) is prepared as outlined in Scheme
1 by reacting a compound of formula (II) or a compound of formula
(III) with a compound of formula (IV). A compound of formula (II)
is reacted with a compound of formula (IV) in the presence of a
base such as Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, Na.sub.2CO.sub.3,
NaOH, KOH, LDA, LHMDS, or the like, in a solvent, for example DMF,
DMA, THF, DME, DCM, and DMSO at a temperature from ambient to about
200.degree. C. In a preferred embodiment the base is selected from
Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, and Na.sub.2CO.sub.3 in a
solvent selected from DMF, DMA. In a particularly preferred
embodiment the base is Cs.sub.2CO.sub.3 and the solvent DMF at a
temperature from 80 to 150.degree. C. One skilled in the art will
recognize that the compound of formula (II) should contain both an
X.sub.1 substituent which is a leaving group, and a R.sub.1 or
R.sub.3 group which is electron-withdrawing in order that the
reaction with a compound of formula (IV) proceed. Preferred R.sub.1
and R.sub.3 substituents include--NO.sub.2, --CHO, --CN,
CO.sub.2R.sub.15, COR.sub.16, --CONR.sub.17R.sub.18, or the like.
Preferred X.sub.1 substituents include --F and --Cl, and --Br.
Particularly preferred R.sub.1 or R.sub.3 substituents include
--NO.sub.2, --CHO, --CN, and COR.sub.16. Particularly preferred
X.sub.1 substituents include --F and --Cl. A compound of formula
(I) may be prepared by reacting a compound of formula (III) with a
compound of formula (IV) according to the Mitsunobu procedure (in
the presence of triphenylphosphine or polymer supported triphenyl
phosphine and DBAD or DEAD, in an organic solvent such as DCM, THF,
and the like), to yield the corresponding compound of formula
(I).
[0230] A compound of formula (VI) is prepared from a compound of
formula (V) as outlined in Scheme 2. 7
[0231] A compound of formula (VI) is prepared by reacting a
compound of formula (V) with a compound of formula (II), or a
compound of formula (III) according to the procedures of Step A and
Step B of Scheme 1, respectively. The group Y.sub.1 represents a
protecting group. One skilled in the art will select the
appropriate protecting group compatible with the desired reactions.
Examples of preferred protecting groups include; carbamates, benzyl
and substituted benzyl groups. Especially preferred protecting
groups are; tert-butyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl,
alpha-chloroethoxycarbonyl, benzyl, 4-nitrobenzyl and
diphenylmethyl.
[0232] A compound of formula (XI) is prepared from a compound of
formula (VI) as outlined in Scheme 3. 8
[0233] Thus in Step A, a compound of formula (VI) in which Y.sub.2
is a nitrogen protecting group is reacted under the appropriate
conditions to obtain a compound of formula (VII). In a preferred
embodiment Y.sub.2 is a benzyl or tert-butoxycarbonyl group which
may be removed via hydrogenolysis or acidic hydrolysis
respectively. In a more preferred embodiment the protecting group
is tert-butoxycarbonyl and is removed with HCl in dioxane. A
compound of formula (VIII) is obtained in Step B by reacting a
compound of formula (VII) and a compound of formula (XXa) in the
presence of a reducing agent such as sodium borohydride, sodium
cyanoborohydride, sodium triacetoxyborohydride, or hydrogen gas or
phenylsilane in the presence of a catalyst, and the like, in a
solvent such as tetrahydrofuran, methanol, ethanol,
1,2-dichloroethane, trifluoroethanol, and the like, to yield the
compound of formula (VIII). One skilled in the art will recognize
that addition of acid to decrease the pH of the reaction mixture to
a pH of less than about 7 may be necessary to effect reaction,
wherein the acid is added as needed and is such as acetic acid,
hydrochloric acid, and the like. Preferred reducing agents are
sodium cyanoborohydride or sodium triacetoxyborohydride. A compound
of formula (IX) is prepared from a compound of formula (VIII) in
Step C by reacting a compound of formula (VIII), wherein R.sub.3 is
--CN, with a reducing agent. A preferred reducing agent is DIBAL in
toluene at a temperature form -78.degree. C. to ambient
temperature, preferably at 0.degree. C. A compound of formula (XI)
is prepared from a compound of formula (IX) in Step D, by reacting
a compound of formula (IX) with a compound of formula (X) in the
presence of a reducing agent such as sodium borohydride, sodium
cyanoborohydride, sodium triacetoxyborohydride, hydrogen gas in the
presence of a catalyst, and the like, in a solvent such as
methanol, ethanol, 1,2-dichloroethane, trifluoroethanol, and the
like. One skilled in the art will recognize that addition of acid
to decrease the pH of the reaction mixture to a pH of less than
about 7 may be necessary to effect reaction, wherein the acid is
added as needed and is such as acetic acid, hydrochloric acid, and
the like. One skilled in the art will furthermore recognize that a
substituted or unsubstituted nonaromatic heterocycle containing
secondary amine functionality may be used in place of the compound
of formula (X). Preferred reducing agents are sodium
cyanoborohydride or sodium triacetoxyborohydride. In an alternative
embodiment a compound of formula (XI) is obtained from a compound
of formula (VI). Thus a compound of formula (XII) is obtained from
a compound of formula (VI) using the conditions of Step C. A
compound of formula (XIII) is obtained from a compound of formula
(XII) by reacting a compound of formula (XII) with a compound of
formula (X) according to the conditions of Step D. A compound of
formula (XIV) is obtained from a compound of formula (XIII)
according to the conditions of Step A. A compound of formula (XI)
is obtained from a compound of formula (XIV) by reacting a compound
of formula (XIV) with a compound of formula (XXa) according to the
procedure of Step B.
[0234] A compound of formula (XVI) is prepared from a compound of
formula (IX), and a compound of formula (XVII) is prepared from a
compound of formula (XII) as outlined in Scheme 4. 9
[0235] A compound of formula (XVI) is prepared from a compound of
formula (IX) by reacting a compound of formula (IX) with a compound
of formula (XV). Thus a compound of formula (XVI) is reacted with a
compound of formula (XV) in the presence of sodium metabisulfite in
DMA at 80 to 120.degree. C. to give a compound of formula (XVI). In
a further embodiment a compound of formula (XII), wherein Y.sub.2
is a protecting group, is reacted with a compound of formula (XV)
under the same conditions to give a compound of formula (XVII).
[0236] A compound of formula (XXI), formula (XXIII) and formula
(XIX) is prepared as outlined in Scheme 5. 10
[0237] A compound of formula (XXI) is prepared from a compound of
formula (I) in which R.sub.3 is halogen by reacting a compound of
formula (XXII) according to the Sonogashira coupling or Heck
coupling procedures. In both cases the preferred halogen is Br and
I with I being especially preferred. In a preferred embodiment a
compound of formula (I) is reacted with a compound of formula
(XXII) in the presence of a palladium catalyst and in the presence
or absence of a copper catalyst. In a more preferred embodiment the
catalyst is selected from; Pd.sub.2(dba).sub.3, PdCl.sub.2 and
Pd(OAc).sub.2 with or without a phosphine additive. Preferred
additives are triphenylphosphine and tri-(tert-butyl)phosphine.
When the compound of formula (XXII) contains a triple bond (that
is, when XXII is a terminal acetylene) an additional copper
catalyst may be desirable. A preferred catalyst is a Cu(I) halide
with CuI being especially preferred. A further preferred embodiment
includes catalysts, together with a base selected from an amine,
Na.sub.2CO.sub.3, K.sub.2CO.sub.3, or the like. A particularly
preferred base is aqueous K.sub.2CO.sub.3. These reactions are
carried out in a solvent selected from, THF, DMF, DME, DMA,
benzene, toluene, DCM, or the like. Preferred solvents are THF and
DME at from ambient temperature to the boiling point of the
solvent. A compound of formula (XXIII) is prepared from a compound
of formula (I) by reacting a compound of formula (I) where R.sub.3
is halogen, preferably I, with a compound of formula (XXIV),
according to the Suzuki procedure, in the presence of a catalyst
such as tetrakis(triphenylphosphine) palladium (0), and the like,
in the presence of a base such as sodium carbonate, potassium
carbonate. A compound of formula (XIX) is prepared from a compound
of formula (I). Thus a compound of formula (I), in which R.sub.3 is
halogen, preferably Br and I, is reacted with an organolithium
reagent and subsequently with a compound of formula (XXb), in a
solvent to give a compound of formula (XVIII). In a preferred
embodiment the organolithium reagent is n-BuLi in THF at a
temperature from -100 to 0.degree. C., preferably at -78.degree. C.
A compound of formula (XIX) is prepared from a compound of formula
(XVIII) by reacting a compound of formula (XVIII) with a reducing
agent, such as sodium borohydride, or sodium cyanoborohydride in
the presence of an acid such as HCl, AcOH, TFA, or the like, in a
solvent such as THF and ether. In an alternative embodiment the
compound of formula (XVIII) may be reacted with either hydrogen in
the presence of a catalyst such as palladium on carbon, or
triethylsilane in the presence of TFA. In preferred embodiment a
compound of formula (XVIII) is reacted with triethylsilane in DCM
at ambient temperature in the presence of TFA.
[0238] A compound of formula (XXV) is prepared from a compound of
formula (XXIV) according to the procedure outlined in Scheme 6.
11
[0239] A compound of formula (XXIV), where Y.sub.1 represents an
oxygen protecting group, is reacted with a compound of formula
(XXVII), where Z.sub.2H represents a heterocycle in which a
nitrogen-hydrogen bond is present, to give a compound of formula
(XXVI) where the group Z.sub.2 is attached via a nitrogen atom. In
a preferred embodiment a compound of formula (XXIV) is reacted with
a compound of formula (XXVII) in the presence of Cu(OAc).sub.2, in
the presence of a base such as pyridine, a dehydrating agent such
as molecular sieves 4A in DCM at ambient temperature to give a
compound of formula (XXVI). Removal of the protecting group Y.sub.1
is accomplished under the appropriate conditions to give a compound
of formula (XXVIII). One skilled in the art would be capable of
selecting an appropriate protecting group. In one embodiment
Y.sub.1 is a substituted benzyl ether, which may be removed upon
treatment with hydrogen in the presence of palladium on carbon. A
compound of formula (XXV) is obtained by reacting a compound of
formula (XXVIII) with a compound of formula (IV) according to the
procedures outlined in Step B of Scheme 1.
[0240] A compound of formula (XXX) is obtained from a compound of
formula (XXIX) as outlined in Scheme 7. 12
[0241] A compound of formula (XXXI) is obtained from a compound of
formula (XXIX) by reacting a compound of formula (XXIX) with a
reducing agent in a solvent. Reducing agents include hydrogen gas
over a catalyst, for example palladium, platinum, Raney nickel or
the like. In a preferred embodiment the reducing agent is
SnCl.sub.2 in ethanol in the presence or absence of water at
ambient temperature to the boiling point of the solvent. A compound
of formula (XXXII) is prepared from a compound of formula (XXXI) by
reacting a compound of formula (XXXI) with a compound of formula
(XXXIII) in which X.sub.2 is a leaving group. In a preferred
embodiment X.sub.2 is Cl and OH. Thus when X.sub.2 is Cl the
compound of formula (XXXI) is reacted with a compound of formula
(XXXIII) in a solvent such as DCM or THF in the presence of a base
such as triethylamine or pyridine. When X.sub.2 is OH a compound of
formula (XXXI) is reacted with a compound of formula (XXXIII) via
peptide coupling, for example in the presence of DCC in a solvent
such as DCM or THF. A compound of formula (XXX) is prepared from a
compound of formula (XXXII) using a reducing agent. Reducing agents
include; BH.sub.3:THF, and BH.sub.3:Me.sub.2S. A preferred reducing
agent is BH.sub.3:Me.sub.2S, in THF at elevated temperature,
preferably at the boiling point of the solvent.
[0242] A compound of formula (XXXV) may be prepared according to
the processes outlined in Scheme 8. 13
[0243] A compound of formula (XXXIV) is reacted with a compound of
formula (X) in the presence of a reducing agent such as sodium
borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride,
hydrogen gas in the presence of a catalyst, and the like, in a
solvent such as methanol, ethanol, 1,2-dichloroethane,
trifluoroethanol, and the like, to yield the compound of formula
(XXXVI). One skilled in the art will recognize that addition of
acid to decrease the pH of the reaction mixture to a pH of less
than about 7 may be necessary to effect reaction, wherein the acid
is added as needed and is such as acetic acid, hydrochloric acid,
and the like. One skilled in the art will furthermore recognize
that a substituted or unsubstituted nonaromatic heterocycle
containing secondary amine functionality may be used in place of
the compound of formula (X). A compound of formula (XXXVI) is
reacted with a compound of formula (IV) according to the procedure
of Step B, Scheme 1, to give a compound of formula (XXXV).
[0244] Compounds of formula (XXXVIII) may be prepared according to
the processes outlined in Scheme 9. 14
[0245] A compound of formula (XXXVII) where R.sub.3 is selected
from Br and I, preferably I, is reacted with a compound of formula
(XXXIX) in the presence of a catalyst such as
tris(dibenzylidineacetone)dipalladium(0), and the like, in the
presence of a base such as sodium t-butoxide, cesium carbonate,
triethylamine, potassium carbonate, and the like, in an organic
solvent such as THF or dioxane, and the like, preferably in the
presence of BINAP (2,2'-bis(diphenylphosphino)-1,1'-dinaphthyl) and
18-Crown-6 (a crown ether), to yield the corresponding compound of
formula (XL). A compound of formula (XLI) may be obtained from a
compound of formula (XL) via the removal of the protecting group
Y.sub.1 followed by reaction with the compound of formula (IV)
according to the procedures of Scheme 1, Step B. A compound of
formula (XLII) is prepared from a compound of formula (XLI) via
removal of the protecting group Y.sub.2. One skilled in the art
will further recognize and understand the concept of orthogonal
protection such that the groups Y.sub.1 and Y.sub.2 may be removed
separately and at the appropriate points in the Scheme. A compound
of formula (XXXVIII) is prepared from a compound of formula (XLII)
by reacting a compound of formula (XLII) with a compound of formula
(XXc) in the presence of a reducing agent such as sodium
borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride,
hydrogen gas in the presence of a catalyst, and the like, in a
solvent such as methanol, ethanol, 1,2-dichloroethane,
trifluoroethanol, and the like, to yield the compound of formula
(XXXVII). One skilled in the art will recognize that addition of
acid to decrease the pH of the reaction mixture to a pH of less
than about 7 may be necessary to effect reaction, wherein the acid
is added as needed and is such as acetic acid, hydrochloric acid,
and the like.
[0246] A compound of formula (XLIV) is prepared from a compound of
formula (XLIII) according to the procedure outlined in Scheme 10.
15
[0247] Compounds of formula (XLIII) are reacted with compounds of
formula (IV) according to the procedure of Step B, Scheme 1 to give
compounds of formula (XLV). Removal of the protecting group Y.sub.1
affords compound of formula (XLVI). In a preferred embodiment the
group Y.sub.1 is a benzyl group, thus the compound of formula (XLV)
is reacted with hydrogen or ammonium formate in the presence of a
catalyst such as palladium on carbon, or the like, in a solvent
such as methanol, ethanol and the like (i.e. catalytic
hydrogenolysis) to yield the corresponding compound of formula
(XLVI). The compound of formula (XLVI) is reacted with a compound
of formula (XXXVII) where X.sub.3 is selected from the group
consisting Cl, Br, I, tosylate, mesylate, and the like, in the
presence of a base such as sodium hydroxide, TEA, sodium hydride,
potassium carbonate, and the like, in an organic solvent such as
DCM, THF, DMF, DMA, and the like, to yield the corresponding
compound of formula (XLIV). In an alternative embodiment the
compound of formula (XXXVII) where X.sub.3 is OH is reacted with a
compound of formula (XLVI) according to the procedures of Step B,
Scheme 1.
[0248] D. Formulation, Administration, and Therapy
[0249] The disclosed compounds, alone or in combination (with, for
example, a histamine H.sub.1 receptor antagonist), are useful for
treating or preventing neurologic disorders including sleep/wake
and arousal/vigilance disorders (e.g. insomnia and jet lag),
attention deficit hyperactivity disorders (ADHD), learning and
memory disorders, cognitive dysfunction, migraine, neurogenic
inflammation, dementia, mild cognitive impairment (pre-dementia),
Alzheimer's disease, epilepsy, narcolepsy, eating disorders,
obesity, motion sickness, vertigo, schizophrenia, substance abuse,
bipolar disorders, manic disorders and depression, as well as other
histamine H.sub.3 receptor mediated disorders such as upper airway
allergic response, asthma, itch, nasal congestion and allergic
rhinitis in a subject in need thereof.
[0250] 1. Formulation and Administration
[0251] The compounds or compositions of the invention may be
formulated and administered to a subject by any conventional route
of administration, including, but not limited to, intravenous,
oral, subcutaneous, intramuscular, intradermal and parenteral
administration. The quantity of the compound which is effective for
treating each condition may vary, and can be determined by one of
ordinary skill in the art.
[0252] For use in medicine, the salts of the compounds of this
invention refer to non-toxic "pharmaceutically acceptable salts."
Other salts may, however, be useful in the preparation of compounds
according to this invention or of their pharmaceutically acceptable
salts. Suitable pharmaceutically acceptable salts of the compounds
include acid addition salts which may, for example, be formed by
mixing a solution of the compound with a solution of a
pharmaceutically acceptable acid such as hydrochloric acid,
sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic
acid, benzoic acid, citric acid, tartaric acid, carbonic acid or
phosphoric acid. Furthermore, where the compounds of the invention
carry an acidic moiety, suitable pharmaceutically acceptable salts
thereof may include alkali ml salts, e.g., sodium or potassium
salts; alkaline earth ml salts, e.g., calcium or magnesium salts;
and salts formed with suitable organic ligands, e.g., quaternary
ammonium salts.
[0253] Thus, representative pharmaceutically acceptable salts
include the following: acetate, benzenesulfonate, benzoate,
bicarbonate, bisulfate, bitartrate, borate, bromide, calcium
edetate, camsylate, carbonate, chloride, clavulanate, citrate,
dihydrochloride, edetate, edisylate, estolate, esylate, fumarate,
gluceptate, gluconate, glutamate, glycollylarsanilate,
hexylresorcinate, hydrabamine, hydrobromide, hydrochloride,
hydroxynaphthoate, iodide, isothionate, lactate, lactobionate,
laurate, malate, maleate, mandelate, mesylate, methylbromide,
methylnitrate, methylsulfate, mucate, napsylate, nitrate,
N-methylglucamine ammonium salt, oleate, pamoate (embonate),
palmitate, pantothenate, phosphate/diphosphate, polygalacturonate,
salicylate, stearate, sulfate, subacetate, succinate, tannate,
tartrate, teoclate, tosylate, triethiodide and valerate.
[0254] The present invention includes within its scope prodrugs of
the compounds of this invention. In general, such prodrugs will be
functional derivatives of the compounds which are readily
convertible in vivo into the required compound. Thus, in the
methods of treatment of the present invention, the term
"administering" shall encompass the treatment of the various
disorders described with the compound specifically disclosed or
with a compound which may not be specifically disclosed, but which
converts to the specified compound in vivo after administration to
the patient. Conventional procedures for the selection and preption
of suitable prodrug derivatives are described, for example, in
"Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. In addition
to salts, the invention provides the esters, amides, and other
protected or derivatized forms of the described compounds.
[0255] Where the compounds according to this invention have at
least one chiral center, they may accordingly exist as enantiomers.
Where the compounds possess two or more chiral centers, they may
additionally exist as diastereomers. It is to be understood that
all such isomers and mixtures thereof are encompassed within the
scope of the present invention. Furthermore, some of the
crystalline forms for the compounds may exist as polymorphs and as
such are intended to be included in the present invention. In
addition, some of the compounds may form solvates with water (i.e.,
hydrates) or common organic solvents, and such solvates are also
intended to be encompassed within the scope of this invention.
[0256] The present invention also provides pharmaceutical
compositions comprising one or more compounds of this invention in
association with a pharmaceutically acceptable carrier and
optionally additional pharmaceutical agents such as H.sub.1
antagonists or SSRIs. Preferably these compositions are in unit
dosage forms such as pills, tablets, caplets, capsules (each
including immediate release, timed release and sustained release
formulations), powders, granules, sterile parenteral solutions or
suspensions (including syrups and emulsions), metered aerosol or
liquid sprays, drops, ampoules, autoinjector devices or
suppositories; for oral parenteral, intranasal, sublingual or
rectal administration, or for administration by inhalation or
insufflation. Alternatively, the composition may be presented in a
form suitable for once-weekly or once-monthly administration; for
example, an insoluble salt of the active compound, such as the
decanoate salt, may be adapted to provide a depot preparation for
intramuscular injection. For preparing solid compositions such as
tablets, the principal active ingredient is mixed with a
pharmaceutical carrier, e.g. conventional tableting ingredients
such as corn starch, lactose, sucrose, sorbitol, talc, stearic
acid, magnesium stearate, dicalcium phosphate or gums, and other
pharmaceutical diluents, e.g. water, to form a solid preformulation
composition containing a homogeneous mixture of a compound of the
present invention, or a pharmaceutically acceptable salt thereof.
When referring to these preformulation compositions as homogeneous,
it is meant that the active ingredient is dispersed evenly
throughout the composition so that the composition may be readily
subdivided into equally effective dosage forms such as tablets,
pills and capsules. This solid preformulation composition is then
subdivided into unit dosage forms of the type described above
containing from 5 to about 1000 mg of the active ingredient of the
present invention. Examples include 5 mg, 7 mg, 10 mg, 15 mg, 20
mg, 35 mg, 50 mg, 75 mg, 100 mg, 120 mg, 150 mg, and so on. The
tablets or pills of the disclosed compositions can be coated or
otherwise compounded to provide a dosage form affording the
advantage of prolonged action. For example, the tablet or pill can
comprise an inner dosage and an outer dosage component, the latter
being in the form of an envelope over the former. The two
components can be septed by an enteric layer which serves to resist
disintegration in the stomach and permits the inner component to
pass intact into the duodenum or to be delayed in release. A
variety of material can be used for such enteric layers or
coatings, such materials including a number of polymeric acids with
such materials as shellac, cetyl alcohol and cellulose acetate.
[0257] The liquid forms in which the compounds and compositions of
the present invention may be incorporated for administration orally
or by injection include, aqueous solutions, suitably flavoured
syrups, aqueous or oil suspensions, and flavoured emulsions with
edible oils such as cottonseed oil, sesame oil, coconut oil or
peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Suitable dispersing or suspending agents for aqueous suspensions,
include synthetic and natural gums such as tragacanth, acacia,
alginate, dextran, sodium carboxymethylcellulose, methylcellulose,
polyvinyl-pyrrol idone or gelatin.
[0258] Where the processes for the preparation of the compounds
according to the invention give rise to mixture of stereoisomers,
these isomers may be separated by conventional techniques such as
preparative chromatography. The compounds may be prepared in
racemic form, or individual enantiomers may be prepared either by
enantiospecific synthesis or by resolution. The compounds may, for
example, be resolved into their component enantiomers by standard
techniques, such as the formation of diastereomeric pairs by salt
formation with an optically active acid, such as
(-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric
acid followed by fractional crystallization and regeneration of the
free base. The compounds may also be resolved by formation of
diastereomeric esters or amides, followed by chromatographic
separation and removal of the chiral auxiliary. Alternatively, the
compounds may be resolved using a chiral HPLC column.
[0259] Advantageously, compounds of the present invention may be
administered in a single daily dose, or the total daily dosage may
be administered in divided doses of two, three or four times daily.
Furthermore, compounds for the present invention can be
administered in intranasal form via topical use of suitable
intranasal vehicles, or via transdermal skin patches well known to
those of ordinary skill in that art. To be administered in the form
of a transdermal delivery system, the dosage administration will,
of course, be continuous rather than intermittent throughout the
dosage regimen.
[0260] For instance, for oral administration in the form of a
tablet or capsule, the active drug component can be combined with
an oral, non-toxic pharmaceutically acceptable inert carrier such
as ethanol, glycerol, water and the like. Moreover, when desired or
necessary, suitable binders, lubricants, disintegrating agents and
coloring agents can also be incorporated into the mixture. Suitable
binders include, without limitation, starch, gelatin, natural
sugars such as glucose or beta-lactose, corn sweeteners, natural
and synthetic gums such as acacia, tragacanth or sodium oleate,
sodium stearate, magnesium stearate, sodium benzoate, sodium
acetate, sodium chloride and the like. Disintegrators include,
without limitation, starch, methyl cellulose, agar, bentonite,
xanthan gum and the like.
[0261] The compound of the present invention can also be
administered in the form of liposome delivery systems, such as
small unilamellar vesicles, large unilamellar vesicles, and
multilamellar vesicles. Liposomes can be formed from a variety of
phospholipids, such as cholesterol, stearylamine or
phophatidylcholines.
[0262] Compounds of the present invention may also be delivered by
the use of monoclonal antibodies as individual carriers to which
the compound molecules are coupled. The compounds of the present
invention may also be coupled with soluble polymers as targetable
drug carriers. Such polymers can include polyvinylpyrrolidone,
pyran copolymer, polyhydroxypropylmethacrylamidephenol,
polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine
substituted with palmitoyl residue. Furthermore, the compounds of
the present invention may be coupled to a class of biodegradable
polymers useful in achieving controlled release of a drug, for
example, polylactic acid, polyepsilon caprolactone, polyhydroxy
butyric acid, polyoesters, polyacetals, polydihydropyrans,
polycyanoacrylates and cross-linked or amphipathic block copolymers
of hydrogels.
[0263] Compounds of this invention may be administered in any of
the foregoing compositions and according to dosage regimens
established in the art whenever treatment of ADHD is required.
[0264] The daily dosage of the products may be varied over a wide
range from 1 to 1,000 mg per adult human per day. For oral
administration, the compositions are preferably provided in the
form of tablets containing 1.0, 5.0, 10.0, 15.0, 25.0, 50.0, 100,
250 and 500 milligrams of the active ingredient for the symptomatic
adjustment of the dosage to the subject to be treated. An effective
amount of the drug is ordinarily supplied at a dosage level of from
about 0.01 mg/kg to about 20 mg/kg of body weight per day.
Preferably, the range is from about 0.02 mg/kg to about 10 mg/kg of
body weight per day, and especially from about 0.05 mg/kg to about
10 mg/kg of body weight per day. The compounds may be administered
on a regimen of 1 to 4 times per day.
[0265] Optimal dosages to be administered may be readily determined
by those skilled in the art, and will vary with the particular
compound used, the mode of administration, the strength of the
preparation, the mode of administration, and the advancement of the
disease condition. In addition, factors associated with the
particular patient being treated, including patient age, weight,
diet and time of administration, will result in the need to adjust
dosages.
[0266] 2. Combination Therapy
[0267] The disclosed compounds are useful in combination with other
therapeutic agents, including H.sub.1 receptor antagonists, H.sub.2
receptor antagonists, and neurotransmitter modulators such as SSRIs
and non-selective serotonin re-uptake inhibitors (NSSRIs).
[0268] Methods are known in the art for determining effective doses
for therapeutic and prophylactic purposes for the disclosed
pharmaceutical compositions or the disclosed drug combinations,
whether or not formulated in the same composition. For therapeutic
purposes, the term "jointly effective amount" as used herein, means
that amount of each active compound or pharmaceutical agent, alone
or in combination, that elicits the biological or medicinal
response in a tissue system, animal or human that is being sought
by a researcher, veterinarian, medical doctor or other clinician,
which includes alleviation of the symptoms of the disease or
disorder being treated. For prophylactic purposes (i.e., inhibiting
the onset or progression of a disorder), the term "jointly
effective amount" refers to that amount of each active compound or
pharmaceutical agent, alone or in combination, that inhibits in a
subject the onset or progression of a disorder as being sought by a
researcher, veterinarian, medical doctor or other clinician, the
delaying of which disorder is mediated, at least in part, by the
modulation of one or more histamine receptors. Thus, the present
invention provides combinations of two or more drugs wherein, for
example, (a) each drug is administered in an independently
therapeutically or prophylactically effective amount; (b) at least
one drug in the combination is administered in an amount that is
sub-therapeutic or sub-prophylactic if administered alone, but is
therapeutic or prophylactic when administered in combination with
the second or additional drugs according to the invention; or (c)
both drugs are administered in an amount that is sub-therapeutic or
sub-prophylactic if administered alone, but are therapeutic or
prophylactic when administered together. Combinations of three or
more drugs are analogously possible. Methods of combination therapy
include co-administration of a single formulation containing all
active agents; essentially contemporaneous administration of more
than one formulation; and administration of two or more active
agents separately formulated.
E. Examples
Example 1
[0269] 16
4-Piperidin-1-ylmethyl-phenol
[0270] A solution of 4-hydroxybenzaldehyde (10 g), piperidine (8.9
mL), and acetic acid (4.7 mL) in DCE (200 mL) was treated with
sodium triacetoxyborohydride (24 g). After 16 h, the resulting
mixture was treated with saturated aqueous sodium bicarbonate (100
mL) and extracted with DCM (5.times.100 mL). The combined organic
phases were dried (magnesium sulfate) and evaporated. Trituration
of the residue with ethyl acetate gave the title compound as a
white crystalline solid (5.5 g).
Example 2
[0271] 17
4-(1-Isopropyl-piperidin-4-yloxy)-benzaldehyde
[0272] A suspension of the product of Example 3 (5.7 g),
4-fluorobenzaldehyde (1.7 mL), and cesium carbonate (13 mg) in DMF
(40 mL) was heated to 100.degree. C. for 22 h, and allowed to cool
to RT. Water (100 mL) was added, and the resulting mixture was
extracted with ether (3.times.100 mL). The combined organic phases
were dried (magnesium sulfate) and evaporated. Chromatography of
the residue (0-15% 2M methanolic ammonia) gave the title compound
as a colorless oil (2.0 g). .sup.1H NMR (400 MHz, CDCl.sub.3): 9.86
(s, 1H), 7.81 (d, J=8.6 Hz, 2H), 6.99 (d, J=8.6 Hz, 2H), 4.43 (m, 1
H), 2.82-2.72 (m, 3H), 2.42 (m, 4H), 2.08-2.00 (m, 2H), 1.89-1.80
(m, 2H), 1.06 (d, J=6.6 Hz, 6H).
Example 3
[0273] 18
[0274] A solution of 1-isopropyl-piperidin-4-one (51.2 g) in
absolute ethanol (350 mL) was treated with sodium borohydride (7.30
g) at a rate not to exceed an internal temperature of 50.degree. C.
After 48 h, the solvent was evaporated and the resulting yellow
paste was partitioned between DCM (300 mL) and 5% NaOH (300 mL).
This mixture was stirred for 6 h and then extracted with DCM
(4.times.100 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Distillation of the yellow oil (bp
68.degree. C., 1.5 mm Hg) gave the title compound as an off-white
waxy solid (35.3 g).
Example 4
[0275] 19
4-[4-(1-tert-Butoxycarbonyl-piperidin-4-yloxy)-phenyl]-piperazine-1-carbox-
ylic acid tert-butyl ester
[0276] A suspension of 4-(4-Hydroxy-phenyl)-piperazine-1-carboxylic
acid tert-butyl ester (3.11 g), 4-Hydroxy-piperidine-1-carboxylic
acid tert-butyl ester (3.51 g), and polymer supported
triphenylphosphine (6.25 g; loading: 3 mmol/g) in DCM (100 mL) was
treated with di-tert-butylazodicarboxylate (3.78 g). After 24 h,
the resulting mixture was filtered, and the filtrate was
evaporated. Chromatography of the residue (15-30% ethyl
acetate/hexanes) gave the title compound as a white solid (3.20
g).
Example 5
[0277] 20
[0278] A solution of 4-hydroxy-piperidine-1-carboxylic acid
tert-butyl ester (14.99 g) and 4-chlorobenzonitrile (10.35 g) in
DMF (100 mL) was treated with sodium hydride (60%, 3.8 g). The
resulting dark mixture was then heated to 65 C. for 16 h, and
allowed to cool to RT. The mixture was poured into water (1 L) and
extracted with ether (3.times.400 mL). The combined organic phases
were evaporated and the brown oil dissolved in methanol (500 mL)
and treated with concentrated hydrochloric acid (20 mL). After 24 h
the methanol was removed, 5% aqueous sodium hydroxide (300 mL) and
water (300 mL) were added, and the mixture was extracted with DCM
(3.times.300 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Bulb to bulb distillation of the residue
gave the title compound as an off white waxy solid (12.23 g).
Example 6
[0279] 21
4-(4-Imidazol-1-yl-phenoxy)-piperidine
[0280] A solution of 4-hydroxy-piperidine-1-carboxylic acid
tert-butyl ester (1.6 g), 4-imidazol-1-yl-phenol (1.2 g), and
triphenylphosphine (2.4 g) in THF (10 mL) was treated with a
solution of di-tert-butylazodicarboxylate (2.1 g) in THF (5 mL).
After 24 h, the resulting mixture was evaporated. Chromatography of
the residue (0-10% 2 M methanolic ammonia/DCM) gave a colorless
glassy solid (1.9 g). This material was dissolved in methanol (10
mL) and treated with 2 M ethereal hydrogen chloride (14 mL). After
24 h, a white solid formed, which was filtered and washed with 1:1
methanol-ether and ether, yielding a white powder (1.2 g). To this
material (1.1 g) was added 10% aqueous sodium hydroxide (20 mL) and
DCM (20 mL). After 10 min vigorous stirring, the resulting mixture
was extracted with DCM (2.times.15 mL). The combined organic phases
were dried (magnesium sulfate) and evaporated, giving the title
compound as a light pink solid (781 mg).
Example 7
[0281] 22
4-(4-Morpholin-4-ylmethyl-phenoxy)-piperidine-1-carboxylic acid
tert-butyl ester
[0282] A suspension of tert-butyl 4-hydroxy-1-piperidinecarboxylate
(32.4 g), 4-flourobenzaldehyde (20.0 g), and cesium carbonate (52.5
g) in DMF (320 mL) was heated to 110 C. for 48 h, and allowed to
cool to RT. Water (400 mL) was added, and the resulting mixture was
extracted with ether (3.times.500 mL). The combined organic phases
were washed with water (3.times.200 mL), brine (200 mL), dried
(magnesium sulfate) and evaporated. Toluene (2.times.200 mL) was
added, and then evaporated, giving a brown-yellow oil (47.2 g). A
solution of this oil (7.0 g), morpholine (2.4 mL), and acetic acid
(1.3 mL) in DCM (300 mL) was treated with sodium
triacetoxyborohydride (5.9 g). After 16 h, the resulting mixture
was treated with 10% aqueous sodium hydroxide (50 mL), and
extracted with DCM (2.times.500 mL). The combined organic phases
were washed with water (100 mL), brine (100 mL), and then dried
(magnesium sulfate) and evaporated. Chromatography of the residue
(0.5 to 5.5% 2 M methanolic ammonia/DCM) gave the title compound as
a yellow solid (6.6 g).
Example 8
[0283] 23
4-[4-(Piperidin-4-yloxy)-benzyl]-morpholine
[0284] A solution of the product of Example 11 (6.6 g) in dioxane
(40 mL) was treated with 4 N hydrogen chloride in dioxane (30 mL).
The resulting mixture was stirred at RT for 16 h. Solvent was
evaporated and the residue was treated with 10% aqueous sodium
hydroxide (50 mL). The resulting mixture was extracted with DCM
(2.times.500 mL). The combined organic phases were washed with
water (200 mL), brine (200 mL), dried (magnesium sulfate), and
evaporated to give the title compound as a yellow oil (5.4 g).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.21 (d, J=8.6 Hz, 2H), 6.86 (d,
J=8.6 Hz, 2H), 4.38-4.34 (m, 1H), 3.70 (t, J=4.6 Hz, 4H), 3.43 (s,
2H), 3.19-3.13 (m, 2H), 2.42 (t, J=4.3 Hz, 2H), 2.10-2.00 (m, 2H),
1.73-1.65 (m, 2H).
Example 9
[0285] 24
1-[4-(Piperidin-4-yloxy)-benzyl]-piperidine
[0286] A suspension of tert-butyl 4-hydroxy-1-piperidinecarboxylate
(32.4 g), 4-fluorobenzaldehyde (20.0 g), and cesium carbonate (52.5
g) in DMF (320 mL) was heated to 110 C. for 48 h and allowed to
cool to RT. Water (400 mL) was added, and the resulting mixture was
extracted with ether (3.times.500 mL). The combined organic phases
were washed with water (3.times.200 mL), brine (200 mL), dried
(magnesium sulfate) and evaporated. The residue was twice treated
with toluene (2.times.200 mL) and evaporated, giving a brown-yellow
oil (47.2 g). A solution of this oil (7.0 g), piperidine (2.8 mL),
and acetic acid (1.3 mL) in DCM (300 mL) was treated with sodium
triacetoxyborohydride (5.9 g). After 16 h, the resulting mixture
was treated with 10% aqueous sodium hydroxide (50 mL), and
extracted with DCM (2.times.500 mL). The combined organic phases
were washed with water (100 mL), brine (100 mL), and then dried
(magnesium sulfate) and evaporated. Chromatography of the residue
(0.5 to 5.5% 2 M methanolic ammonia/DCM) gave the title compound as
a yellow oil (8.6 g).
[0287] A solution of this oil (8.6 g) in dioxane (30 mL) was added
4 N hydrogen chloride in dioxane (40 mL). The resulting mixture was
stirred at RT for 16 h and evaporated. The residue was treated with
10% aqueous sodium hydroxide (50 mL) and extracted with DCM
(2.times.500 mL). The combined organic phases were washed with
water (200 mL), brine (200 mL), dried (magnesium sulfate), and
evaporated. Chromatography of the residue (0.5 to 5.5% 2 M
methanolic ammonia/DCM) gave the title compound as an ivory solid
(3.4 g). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.20 (d, J=8.5Hz, 2H),
6.85 (d, J=8.6Hz, 2H), 4.37-4.30 (m, 1H), 3.40 (s, 2H), 3.17-3.11
(m, 2H), 2.75-2.68 (m, 2H), 2.35 (br s, 4H), 2.03-1.99 (m, 2H),
1.69-1.61 (m, 2H), 159-1.53 (m, 2H), 1.43-1.39 (m, 2H).
Example 10
[0288] 25
3-(1-Isopropyl-piperidin-4-yloxy)-benzaldehyde
[0289] A solution of the product of Example 3 (716 mg),
3-hydroxybenzaldehyde (672 mg), and triphenylphosphine (1.6 g) in
THF (5 mL) was treated with a solution of
di-tert-butylazodicarboxylate (1.4 g) in THF (5 mL). After 16 h,
the resulting mixture was evaporated. The residue was treated with
ether (20 mL) and 20% aqueous hydrochloric acid (20 mL). The
aqueous phase was washed with ether (20 mL), neutralized with solid
sodium carbonate, and extracted with ether (3.times.20 mL). The
combined organic phases were dried (magnesium sulfate), and
evaporated. Chromatography of the residue (0-10% 2M methanolic
ammonia/DCM) gave the title compound as a colorless oil (50
mg).
Example 11
[0290] 26
4-[4-(1-Benzyl-piperidin-4-yloxy)-benzyl]-morpholine
[0291] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), benzaldehyde (0.051 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, additional phenylsilane (0.036 mL) was added. After 4 h, the
resulting mixture was filtered through a pad of celite, and the pad
was washed with DCM (3.times.3 mL). The combined filtrates were
chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving the
title compound as a white solid (94 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.33-7.23 (m, 5H), 7.20 (d, J=8.6 Hz, 2H), 6.85 (d,
J=8.6 Hz, 2H), 4.32-4.23 (m, 1H), 3.69 (t, J=4.6 Hz, 4H), 3.53 (s,
2H), 3.42 (s, 2H), 2.77-2.73 (m, 2H), 2.42 (t, J=4.3 Hz, 4H),
2.32-2.26 (m, 2H), 2.02-1.96 (m, 2H), 1.85-1.77 (m, 2H).
Example 12
[0292] 27
4-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-morpholine
[0293] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), cyclohexanone (0.052 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, additional phenylsilane (0.036 mL) was added. After 4 h, the
resulting mixture was filtered through a pad of celite, and the pad
was washed with DCM (3.times.3 mL). The combined filtrates were
chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving the
title compound as a colorless oil (73 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.21 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H),
4.33-4.29 (m, 1H), 3.70 (t, J=4.6 Hz, 4H), 3.42 (s, 2H), 2.92-2.86
(m, 2 H), 2.57-2.51 (m, 2H), 2.43-2.28 (m, 7 H), 2.09-2.02 (m, 2H),
1.92-1.81 (m, 6H), 1.31-1.20 (m, 4H).
Example 13
[0294] 28
4-[4-(4-Morpholin-4-ylmethyl-phenoxy)-piperidin-1-yl]-butan-2-one
[0295] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), 4-hydroxy-2-butanone (44 mg)
and scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After
16 h, additional phenylsilane (0.036 mL) was added. After 4 h, the
resulting mixture was filtered through a pad of celite, and the pad
was washed with DCM (3.times.3 mL). The combined filtrates were
chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving the
title compound as a colorless oil (33 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.04 (d, J=8.5 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H),
4.32-4.27 (m, 1H), 3.70 (t, J=4.6 Hz, 4 H), 3.42 (s, 2H), 2.74-2.62
(m, 4H), 2.43 (t, J=4.2 Hz, 4H), 2.33-2.27 (m, 2H), 2.18 (s, 3H),
2.02-1.76 (m, 6H).
Example 14
[0296] 29
4-[4-(1-Cyclohexylmethyl-piperidin-4-yloxy)-benzyl]-morpholine
[0297] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), cyclohexanecarboxaldehyde
(0.061 mL) and scandium trifluoromethanesulfonate (13 mg) in THF (1
mL). After 16 h, additional phenylsilane (0.036 mL) was added.
After 4 h, the resulting mixture was filtered through a pad of
celite, and the pad was washed with DCM (3.times.3 mL). The
combined filtrates were chromatographed (0.5-5.5% 2 M methanolic
ammonia/DCM), giving the title compound as a colorless oil (100
mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.20 (d, J=8.6 Hz, 2H),
6.85 (d, J=8.6 Hz, 2H), 4.29-4.23 (m, 1H), 3.70 (t, J=4.6 Hz, 4H),
3.42 (s, 2H), 2.70 (t, J=4.6 Hz, 2H), 2.43 (t, J=4.2 Hz, 4H), 2.20
(t, J=9.1 Hz, 1H), 2.13 (d, J=7.1 Hz, 1H), 2.00-1.64 (m, 9H),
1.52-1.43 (m, 1H), 1.28-1.13 (m, 3H), 0.91-0.82 (m, 2H).
Example 15
[0298] 30
4-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-morpholine
[0299] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), isobutyraldehyde (0.091 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, additional phenylsilane (0.036 mL) was added. After 4 h, the
resulting mixture was filtered through a pad of celite, and the pad
was washed with DCM (3.times.3 mL). The combined filtrates were
chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving the
title compound as a colorless oil (198 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.20 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H),
4.29-4.23 (m, 1H), 3.70 (t, J=4.7 Hz, 4H), 3.42 (s, 2H), 2.72-2.69
(m, 2H), 2.42 (t, J=4.4 Hz, 4H), 2.19 (t, J=9.0 Hz, 1H), 2.09 (d,
J=7.3 Hz, 1H), 2.00-1.95 (m, 2H), 1.83-1.72 (m, 3H), 0.90 (d, J=6.6
Hz, 6H).
Example 16
[0300] 31
4-[4-(1-Propyl-piperidin-4-yloxy)-benzyl]-morpholine
[0301] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), propionaldehyde (0.072 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, additional phenylsilane (0.036 mL) was added. After 4 h, the
resulting mixture was filtered through a pad of celite, and the pad
was washed with DCM (3.times.3 mL). The combined filtrates were
chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving the
title compound as a colorless oil (85 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.21 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H),
4.34-4.28 (m, 1H), 3.70 (t, J=4.7 Hz, 4H), 3.42 (s, 2H), 2.79-2.75
(m, 2H), 2.42 (t, J=4.3 Hz, 4H), 2.37-2.33 (m, 4H), 2.06-1.99 (m,
2H), 1.88-1.80 (m, 2H), 1.59-1.50 (m, 2H), 0.91 (t, J=7.4 Hz,
6H).
Example 17
[0302] 32
4-{4-[1-(1-Methyl-heptyl)-piperidin-4-yloxy]-benzyl}-morpholine
[0303] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of trifluoromethanesulfonate (13 mg) in THF (1 mL).
After 16 h, additional phenylsilane (0.036 mL) was added. After 4
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (108 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.20 (d, J=8.5 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H),
4.29-4.24 (m, 1H), 3.70 (t, J=4.7 Hz, 4H), 3.42 (s, 2H), 2.80-2.73
(m, 2H), 2.60-2.57 (m,1H), 2.48-2.33 (m, 6H), 1.99 (m, 2H),
1.84-1.74 (m, 1H), 1.57-1.54 (m, 9H), 0.94 (d, J=6.5 Hz, 3H),
0.90-0.87 (m, 3H).
Example 18
[0304] 33
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine
[0305] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), 2-butanone (0.089 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, additional phenylsilane (0.036 mL) was added. After 4 h, the
resulting mixture was filtered through a pad of celite, and the pad
was washed with DCM (3.times.3 mL). The combined filtrates were
chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving the
title compound as a colorless oil (75 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.20 (d, J 8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H),
4.29-4.24 (m, 1H), 3.70 (t, J=4.7 Hz, 4H), 3.42 (s, 2H), 2.81-2.73
(m, 2H), 2.51-2.32 (m, 6H), 2.05-1.95 (m, 2H), 1.83-1.75 (m, 2H),
1.62-1.56 (m, 1H), 1.34-1.26 (m, 2H), 0.99 (d, J=6.6 Hz, 3H), 0.90
(t, J=7.4 Hz, 3H).
Example 19
[0306] 34
4-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-morpholine
[0307] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 10 (137 mg), cyclopentanone (0.088 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, additional phenylsilane (0.036 mL) was added. After 4 h, the
resulting mixture was filtered through a pad of celite, and the pad
was washed with DCM (3.times.3 mL). The combined filtrates were
chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving the
title compound as a colorless oil (168 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.22 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H),
4.44-4.35 (m, 1H), 3.70 (t, J=4.7 Hz, 4H), 3.43 (s, 2H), 2.95-2.88
(m, 1H), 2.76-2.54 (m, 2H), 2.42 (t, J 4.4 Hz, 4H), 2.16-2.08 (m,
2H), 1.94-1.91 (m, 4H), 1.78-1.72 (m, 2H), 1.62-1.57 (m, 4H).
Example 20
[0308] 35
4-[4-(4-Piperidin-1-ylmethyl-phenoxy)-piperidin-1-yl]-butan-2-one
[0309] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), 4-hydroxy-2-butanone (44 mg) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (42 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H), 6.83 (d, J=8.6 Hz, 2H),
4.31-4.26 (m, 1H), 3.40 (s, 2H), 2.75-2.61 (m, 4H), 2.36-2.22 (m,
6H), 2.18 (s, 3H), 2.27-1.72 (m, 6H), 1.59-1.53 (m, 4H), 1.47-1.35
(m, 2H).
Example 21
[0310] 36
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-(5-methyl-pyridin-2-yl)-amine
[0311] A solution of the product of Example 2 (175 mg),
2-amino-5-methylpyridine (87 mg), and acetic acid (0.05 mL) in DCE
(3 mL) was treated with sodium triacetoxyborohydride (257 mg).
After 16 h, the resulting mixture was treated with 10% sodium
hydroxide (1 mL), and the mixture was extracted with DCM (3.times.3
mL). The combined organic phases were dried (magnesium sulfate) and
evaporated. Chromatography of the residue (0-8% 2M methanolic
ammonia/DCM) gave the title compound as a yellow waxy solid (103
mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.93 (s, 1H), 7.26-7.21 (m,
3H), 6.86 (d, J=8.6 Hz, 2H), 6.32 (d, J=8.41, 1H), 4.66-4.61 (br m,
1 H), 4.39 (d, J=5.7, 2H), 4.31-4.24 (m,1H), 2.81-2.70 (m, 3H),
2.42-2.34 (m, 2H), 2.17 (s, 3H), 2.04-1.96 (m, 2H), 1.86-1.76 (m,
2H), 1.07 (d, J=6.7, 6H).
Example 22
[0312] 37
(5-Chloro-pyridin-2-yl)-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine
[0313] A solution of the product of Example 2 (200 mg),
2-amino-5-chloropyridine (104 mg), and acetic acid (0.05 mL) in DCE
(3 mL) was treated with sodium triacetoxyborohydride (257 mg).
After 16 h, the resulting mixture was treated with 10% sodium
hydroxide (1 mL), and the mixture was extracted with DCM (3.times.3
mL). The combined organic phases were dried (magnesium sulfate) and
evaporated. Chromatography of the residue (0-8% 2M methanolic
ammonia/DCM) gave the title compound as a yellow amorphous solid
(137 mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 8.05 (s,1H), 7.35 (dd,
J=8.8, 2.5 Hz, 1H), 7.24 (d, J=8.6 Hz, 2H), 6.87 (d, J=8.8 Hz, 2H),
6.32 (d, J=9.0 Hz, 1H), 4.84-4.78 (m, 1H), 4.39 (d, J=5.7 Hz, 2H),
4.31-4.25 (m, 1H), 2.81-2.70 (m, 3H), 2.41-2.35 (m, 2H), 2.05-1.96
(m, 2H), 1.84-1.76 (m, 2H), 1.05 (d, J=6.1 Hz, 6H).
Example 23
[0314] 38
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-phenyl-amine
[0315] A solution of the product of Example 2 (200 mg), aniline
(104 mg), and acetic acid (0.05 mL) in DCE (3 mL) was treated with
sodium triacetoxyborohydride (257 mg). After 16 h, the resulting
mixture was treated with 10% sodium hydroxide (1 mL), and the
mixture was extracted with DCM (3.times.3 mL). The combined organic
phases were dried (magnesium sulfate) and evaporated.
Chromatography of the residue (0-8% 2M methanolic ammonia/DCM) gave
the title compound as a yellow amorphous solid (136 mg). .sup.1H
NMR (400 MHz, CDCl.sub.3): 7.27 (d, J=8.2 Hz, 1H), 7.19-7.15 (m,
2H), 6.89 (d, J=8.6 Hz, 2H), 6.73-6.69 (m, 1H), 6.65-6.62 (m, 2H),
4.31-4.23 (m, 3H), 3.96-3.90 (br s,1H), 2.83-2.70 (m, 3H),
2.43-2.34 (m, 2H), 2.05-1.96 (m, 2H), 1.86-1.76 (m, 2H), 1.06 (d,
J=6.7, 6H).
Example 24
[0316] 39
1-[4-(1-Benzyl-piperidin-4-yloxy)-benzyl]-piperidine
[0317] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), benzaldehyde (0.051 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a white solid (145 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.34-7.23 (m, 5H), 7.21 (d, J=8.6 Hz, 2H), 6.85 (d,
J=8.6 Hz, 2H), 4.32-4.26 (m, 1H), 3.53 (s, 2H), 3.48 (s, 2H), 2.90
(bs, 1H), 2.76-2.72 (m, 2H), 2.43 (bs, 3H), 2.39 (t, J=8.7 Hz, 2H),
2.01-1.96 (m, 2H), 1.85-1.77 (m, 2H), 1.6-1.57 (m, 4H), 1.47-1.38
(m, 2H).
Example 25
[0318] 40
1-[4-(1-Cyclohexyl-piperidin-4-yloxy)-benzyl]-piperidine
[0319] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), cyclohexanone (0.052 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (141 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H),
4.30-4.25 (m, 1H) 3.40 (s, 2H), 2.88-2.83 (m, 2H), 2.50-2.45 (m,
2H), 2.40-2.29 (m, 5H), 2.07-1.74 (m, 8H), 1.65-1.62 (m, 1H),
1.59-1.54 (m, 4H), 1.45-1.42 (m, 4H), 1.30-1.19 (m, 4H), 1.14-1.07
(m,1H).
Example 26
[0320] 41
1-[4-(1-Cyclohexylmethyl-piperidin-4-yloxy)-benzyl]-piperidine
[0321] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), cyclohexanecarbozaldehyde (0.061
mL) and scandium trifluoromethanesulfonate (13 mg) in THF (1 mL).
After 16 h, the resulting mixture was filtered through a pad of
celite, and the pad was washed with DCM (3.times.3 mL). The
combined filtrates were chromatographed (0.5-5.5% 2 M methanolic
ammonia/DCM), giving the title compound as a colorless oil (163
mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.19 (d, J=8.4 Hz, 2H),
6.84 (d, J=8.5 Hz, 2H), 4.27-4.23 (m, 1H), 3.40 (s, 2H), 2.76-2.64
(m, 2H), 2.43-2.28 (bs, 4H), 2.24-2.08 (m, 4H), 2.03-1.92 (m, 2H),
1.65-1.62 (m,1H), 1.85-1.36 (m, 13H), 1.30-1.09 (m, 4H), 0.93-0.79
(m, 2H).
Example 27
[0322] 42
4-[3-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine
[0323] A solution of the product of Example 10 (50 mg) and
morpholine (21 mg) in DCE (2 mL) was treated with sodium
triacetoxyborohydride (64 mg). After 16 h, the resulting mixture
was treated with 10% sodium hydroxide (1 mL), and the mixture was
extracted with DCM (3.times.2 mL). The combined organic phases were
dried (magnesium sulfate) and evaporated. Chromatography of the
residue (0-15% 2M methanolic ammonia/DCM) gave the title compound
as a colorless glassy oil (46 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.20 (t, J=7.6 Hz,1H), 6.91-6.87 (m, 2H), 6.82-6.78
(m, 1H), 4.34-4.27 (m, 1H), 3.71 (t, J=3.71, 4H), 3.46 (s, 2H),
2.83-2.71 (m, 3H), 2.47-2.35 (m, 6H), 2.05-1.97 (m, 2H), 1.86-1.77
(m, 2H), 1.06 (d, J=6.5 Hz, 6H).
Example 28
[0324] 43
1-[4-(1-Propyl-piperidin-4-yloxy)-benzyl]-piperidine
[0325] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), propionaldehyde (0.072 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (105 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.19 (d, J=8.4Hz, 2H), 6.84 (d, J=8.5 Hz, 2H),
4.30-4.26 (m, 1H), 3.40 (s, 2H), 2.75-2.70 (m, 2H), 2.40-2.20 (m,
7H), 2.06-1.93 (m, 2H), 1.86-1.68 (m, 5H), 1.59-1.37 (m, 6H),
0.92-0.86 (m, 3H).
Example 29
[0326] 44
1-[4-(1-Isobutyl-piperidin-4-yloxy)-benzyl]-piperidine
[0327] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), isobutyraldehyde (0.091 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (91 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H),
4.28-4.23 (m, 1H), 3.39 (s, 2H), 2.72-2.69 (m, 2H), 2.35 (bs, 4H),
2.21-2.16 (m, 2H), 2.09 (d, 2H), 2.01-1.95 (m, 3H), 1.59-1.53 (m,
3H), 1.44-1.38 (m, 2H), 0.90 (d, J=6.6 Hz, 6H).
Example 30
[0328] 45
1-{4-[1-(1-Methyl-heptyl)-piperidin-4-yloxy]-benzyl}-piperidine
[0329] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), 2-octanone (0.156 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (228 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.19 (d, J=8.5 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H),
4.28-4.22 (m, 1H), 3.40 (s, 2H), 2.79-2.72 (m, 2H), 2.59-2.55
(m,1H), 2.46-2.31 (m, 6H), 1.83-1.73 (m, 2H), 1.57-1.53 (m, 4H),
1.43-1.38 (m, 8H), 1.32-1.21 (m, 10H), 0.98 (d, J=6.5 Hz, 3H), 0.89
(t, J=6.8 Hz, 3H).
Example 31
[0330] 46
4-[4-(1-sec-Butyl-piperidin-4-yloxy)-benzyl]-morpholine
[0331] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), 2-butanone (0.089 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (164 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H),
4.28-4.22 (m, 1H), 3.39 (s, 2H), 2.89-2.72 (m, 2H), 2.50-2.31 (m,
6H), 1.98-1.95 (m, 2H), 1.83-1.72 (m, 2H), 1.59-1.53 (m, 6H),
1.43-1.37 (m, 2H), 1.34-1.23 (m, 1H), 0.98 (d, J 6.5 Hz, 3H), 0.90
(t, J=7.4 Hz, 3H).
Example 32
[0332] 47
1-[4-(1-Cyclopentyl-piperidin-4-yloxy)-benzyl]-piperidine
[0333] Phenylsilane (0.068 mL) was added dropwise to a solution of
the product of Example 9 (137 mg), cyclopentanone (0.088 mL) and
scandium trifluoromethanesulfonate (13 mg) in THF (1 mL). After 16
h, the resulting mixture was filtered through a pad of celite, and
the pad was washed with DCM (3.times.3 mL). The combined filtrates
were chromatographed (0.5-5.5% 2 M methanolic ammonia/DCM), giving
the title compound as a colorless oil (250 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.19 (d, J=8.5 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H),
4.34-4.23 (m, 1H), 3.39 (s, 2H), 2.87-2.73 (m, 2H), 2.55-2.47 (m,
1H), 2.40-2.26 (m, 6H), 2.05-1.95 (m, 2H), 1.91-1.79 (m, 4H),
1.73-1.49 (m, 8H), 1.46-1.37 (m, 4H).
Example 33
[0334] 48
4-(4-Imidazol-1-yl-phenoxy)-1-isobutyl-piperidine
[0335] A solution of the product of Example 6 (130 mg),
cyclohexanone (0.06 mL), and dibutyltin dichloride (3 mg) in THF
(0.1 mL) was treated with phenylsilane (0.07 mL). After 16 h, the
resulting mixture was chromatographed (0-8% 2M methanolic
ammonia/DCM), giving the title compound as a waxy solid (18 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.75 (t, J=1.2 Hz, 1H), 7.28 (d,
J=9.0 Hz, 2H), 7.20 (t, J=1.4 Hz, 1H), 7.18 (t, J=1.2 Hz, 1H), 6.99
(d, J=8.8 Hz, 2H), 4.35-4.27 (m, 1H), 2.76-2.67 (m, 2H), 2.26-2.18
(m, 2H), 2.10 (d, J 7.24 Hz, 2H), 2.05-1.96 (m, 2H), 1.87-1.73 (m,
3H), 0.90 (d, J=6.5 Hz, 6H).
Example 34
[0336] 49
1-Cyclopentyl-4-(4-imidazol-1-yl-phenoxy)-piperidine
[0337] A solution of the product of Example 6 (130 mg),
isobutyraldehyde (0.06 mL), and dibutyltin dichloride (3 mg) in THF
(0.1 mL) was treated with phenylsilane (0.07 mL). After 16 h, the
resulting mixture was chromatographed (0-8% 2M methanolic
ammonia/DCM), giving the title compound as a waxy solid (57 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.75 (t, J=1.2 Hz, 1H), 7.28 (d,
J=9.0 Hz, 2H), 7.20 (t, J=1.2 Hz, 1H), 7.17 (t, J=1.2 Hz, 1H), 6.99
(d, J=9.0 Hz, 2H), 4.39-4.29 (m, 1H), 2.87-2.77 (br m, 1H),
2.57-2.48 (m, 1H), 2.40-2.30 (m, 2H), 2.08-1.99 (m, 2H), 1.94-1.82
(m, 5H), 1.75-1.64 (m, 2H), 1.61-1.61 (m, 2H), 1.47-1.37 (m,
2H).
Example 35
[0338] 50
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-pyridin-2-yl-amine
[0339] A solution of the product of Example 2 (522 mg),
2-aminopyridine (230 mg), and acetic acid (0.01 3 mL) in DCM (7 mL)
was treated with sodium triacetoxyborohydride (720 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (8 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a yellow solid (417 mg). .sup.1H NMR (400
MHz, CDCl.sub.3): 8.10 (m, 1H), 7.40 (m, 1H), 7.28-7.24 (m, 2H),
6.9-6.85 (m, 2H), 6.58 (m, 1H), 6.37 (m, 1H), 4.77 (m 1H), 4.41 (d,
J=5.8 Hz, 2H), 4.28 (m, 1H), 2.82-2.71 (m, 4H), 2.39 (m, 3H),
2.05-1.97 (m, 3H), 1.85-1.76 (m, 3H), 1.06 (d, J=6.6 Hz, 6H).
Example 36
[0340] 51
4-(1-Ethyl-piperidin-4-yloxy)-benzonitrile
[0341] A solution of the product of Example 5 (226 mg),
acetaldehyde (0.5 mL), and acetic acid (0.09 mL) in DCM (3 mL) was
treated with sodium triacetoxyborohydride (360 mg). After 16 h, the
resulting mixture was treated with 10% sodium hydroxide (5 mL), and
the mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (67 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.53 (d, J=8.8 Hz, 2H), 6.91 (d, J=8.8 Hz, 2H), 4.37
(m, 1H), 2.71 (m, 2H), 2.41 (q, J=7.1, 2H), 2.28 (m, 2H), 1.99 (m,
2H), 1.82 (m, 2H), 1.07 (t, J=7.1, 3H).
Example 37
[0342] 52
4-(1-Phenethyl-piperidin-4-yloxy)-benzonitrile
[0343] A solution of the product of Example 5 (203 mg),
phenylacetaldehyde (0.14 mL), and acetic acid (0.08 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (320 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (145 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.58 (d, J=8.8 Hz, 2H), 7.32-7.28 (m, 2H), 7.21 (m,
3H), 6.94 (d, J=8.8 Hz, 2H), 4.45 (br,1H), 2.84 (br, 4H), 2.66 (br,
2H), 2.42 (br, 1.5H), 2.04 (br, 1.5H), 1.91 (br, 2H), 1.55 (br,
1H).
Example 38
[0344] 53
4-(1-Cyclobutyl-piperidin-4-yloxy)-benzonitrile
[0345] A solution of the product of Example 5 (206 mg),
cyclobutanone (0.1 mL), and acetic acid (0.08 mL) in DCM (3 mL) was
treated with sodium triacetoxyborohydride (320 mg). After 16 h, the
resulting mixture was treated with 10% sodium hydroxide (5 mL), and
the mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (66 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.58 (d, J=8.8 Hz, 2H), 6.93 (d, J=8.8 Hz, 2H), 4.41
(br, 1H), 2.81-2.54 (br, m, 3H), 2.23-1.46 (br, m, 12H).
Example 39
[0346] 54
4-(1-Methyl-piperidin-4-yloxy)-benzonitrile
[0347] A solution of the product of Example 5 (213 mg),
paraformaldehyde (0.52 g), and acetic acid (0.08 mL) in DCM (3 mL)
was treated with sodium triacetoxyborohydride (340 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (5 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (91 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.57 (d, J=9.1 Hz, 2H), 6.93 (d, J=9.1 Hz, 2H), 4.40
(m, 1H), 2.69 (br, 2H), 2.37-2.29 (br, 2H), 2.32 (s, 3H), 2.03 (m,
2H), 1.87 (m, 2H).
Example 40
[0348] 55
4-(1-sec-Butyl-piperidin-4-yloxy)-benzonitrile
[0349] A solution of the product of Example 5 (211 mg), 2-butanone
(0.13 mL), and acetic acid (0.07 mL) in DCM (3 mL) was treated with
sodium triacetoxyborohydride (330 mg). After 16 h, the resulting
mixture was treated with 10% sodium hydroxide (5 mL), and the
mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (91 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.56 (d, J=9.1 Hz, 2H), 6.93 (d, J=9.1 Hz, 2H), 4.36
(br, 1H), 2.77 (br, 2H), 2.50 (br, 2H), 2.37 (br, 1H), 2.02 (br,
2H), 1.81 (br, 2H), 1.58 (br, 1H), 1.30 (m, 1H), 1.0 (br, d, J=6.1
Hz, 3H), 0.91 (t, J=7.3 Hz, 3H).
Example 41
[0350] 56
4-(1-Benzyl-piperidin-4-yloxy)-benzonitrile
[0351] A solution of the product of Example 5 (203 mg),
benzaldehyde (0.13 mL), and acetic acid (0.07 mL) in DCM (3 mL) was
treated with sodium triacetoxyborohydride (330 mg). After 16 h, the
resulting mixture was treated with 10% sodium hydroxide (5 mL), and
the mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (112 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.56 (d, J=8.8 Hz, 2H), 7.33 (m, 3H), 7.27 (m, 2H),
6.93 (d, J=8.8 Hz, 2H), 4.40 (br,1H), 3.54 (br, 2H), 2.73 (br, 2H),
2.32 (br, 2H), 1.99 (br, 2H), 1.84 (br, 2H), 1.56 (br, 1H).
Example 42
[0352] 57
4-[1-(2-Hydroxy-1-methyl-ethyl)-piperidin-4-yloxy]-benzonitrile
[0353] A solution of the product of Example 5 (205 mg),
1-hydroxy-2-propanone (0.14 mL), and acetic acid (0.08 mL) in DCM
(3 mL) was treated with sodium triacetoxyborohydride (330 mg).
After 16 h, the resulting mixture was treated with 10% sodium
hydroxide (5 mL), and the mixture was extracted with DCM
(3.times.10 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Chromatography of the residue (1-7% 2M
methanolic ammonia/DCM) gave the title compound as a white solid
(161 mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.57 (d, J=8.8 Hz,
2H), 6.93 (d, J=8.8 Hz, 2H), 4.42 (m,1H), 3.42 (m, 1H), 3.32 (m,
1H), 2.88 (m, 2H), 2.64 (m, 2H), 2.33 (m,1H), 2.03 (m, 2H), 1.84
(m, 2H), 0.92 (d, J=6.6 Hz, 3H).
Example 43
[0354] 58
4-(1-Cyclohexylmethyl-piperidin-4-yloxy)-benzonitrile
[0355] A solution of the product of Example 5 (221 mg),
cyclohexanecarboxaldehyde (0.2 mL), and acetic acid (0.08 mL) in
DCM (3 mL) was treated with sodium triacetoxyborohyd ride (340 mg).
After 16 h, the resulting mixture was treated with 10% sodium
hydroxide (5 mL), and the mixture was extracted with DCM
(3.times.10 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Chromatography of the residue (1-7% 2M
methanolic ammonia/DCM) gave the title compound as a white solid
(205 mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.57 (d, J=9.1 Hz,
2H), 6.93 (d, J=9.1 Hz, 2H), 4.37 (br, 1H), 2.69 (br, 2H), 2.22
(br, 2H), 2.14 (br, 2H), 1.98 (br, 2H), 1.86-1.63 (m, 7H), 1.47
(br, 1H), 1.29-1.10 (m, 3H), 0.88 (m, 2H).
Example 44
[0356] 59
4-(1-Cyclohexyl-piperidin-4-yloxy)-benzonitrile
[0357] A solution of the product of Example 5 (202 mg),
cyclohexanone (0. 17 mL), and acetic acid (0.08 mL) in DCM (3 mL)
was treated with sodium triacetoxyborohydride (340 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (5 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (241 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.56 (d, J=8.8 Hz, 2H), 6.93 (d, J=8.8 Hz, 2H), 4.37
(m, 1H), 2.84 (m, 2H), 2.47 (m, 2H), 2.32 (b, 1H), 2.01 (br, 2H),
1.89-1.77 (m, 6H), 1.63 (m, 1H), 1.30-1.17 (m, 4H), 1.10 (m,
1H).
Example 45
[0358] 60
4-(1-Cyclopentyl-piperidin-4-yloxy)-benzonitrile
[0359] A solution of the product of Example 5 (210 mg),
cyclopentanone (0.14 mL), and acetic acid (0.08 mL) in DCM (3 mL)
was treated with sodium triacetoxyborohydride (330 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (5 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (237 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.57 (d, J=8.8 Hz, 2H), 6.94 (d, J=8.9 Hz, 2H), 4.40
(br, 1H), 2.91-2.23 (brr, m, 5H), 2.13-1.35 (m 12H).
Example 46
[0360] 61
4-(1-Propyl-piperidin-4-yloxy)-benzonitrile
[0361] A solution of the product of Example 5 (211 mg),
propanaldehyde (0.15 mL), and acetic acid (0.07 mL) in DCM (3 mL)
was treated with sodium triacetoxyborohydride (330 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (5 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (64 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.57 (d, J=9.1 Hz, 2H), 6.93 (d, J=9.1 Hz, 2H), 4.42
(br, 1H), 2.76 (br, 2H), 2.35 (br, 3H), 2.05 (br, 2H), 1.87 (br,
2H), 1.56 (br, 2H), 0.92 (t, J=7.3 Hz, 3H).
Example 47
[0362] 62
4-(1-Isobutyl-piperidin-4-yloxy)-benzonitrile
[0363] A solution of the product of Examples 5 (202 mg),
isobutyraldehyde (0.21 mL), and acetic acid (0.07 mL) in DCM (3 mL)
was treated with sodium triacetoxyborohydride (360 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (5 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (211 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.56 (d, J=9.1 Hz, 2H), 6.93 (d, J=9.1 Hz, 2H), 4.37
(br, 1H), 2.69 (br, 2H), 2.22 (br, 2H), 2.09 (br, 2H), 1.98 (br,
2H), 187-1.73 (m, 3H), 0.90 (d, br, J=7.3 Hz, 6H).
Example 48
[0364] 63
4-(1-Cyclopropylmethyl-piperidin-4-yloxy)-benzonitrile
[0365] A solution of the product of Example 5 (215 mg),
cyclopropanecarboxaldehyde (0.16 mL), and acetic acid (0.07 mL) in
DCM (3 mL) was treated with sodium triacetoxyborohydride (340 mg).
After 16 h, the resulting mixture was treated with 10% sodium
hydroxide (5 mL), and the mixture was extracted with DCM
(3.times.10 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Chromatography of the residue (1-7% 2M
methanolic ammonia/DCM) gave the title compound as a white solid
(173 mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.56 (d, J=9.1 Hz,
2H), 6.93 (d, J=9.1 Hz, 2H), 4.40 (m, 1H), 2.83 (m, 2H), 2.40 (m,
2H), 2.29 (d, J=6.6 Hz, 2H), 2.03 (m, 2H), 1.87 (m, 2H), 0.88 (m,
1H), 0. 52 (m, 2H), 0.11 (m, 2H).
Example 49
[0366] 64
5-Chloro-2-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-1H-benzoimidazole
[0367] A solution of the product of Example 2 (260 mg),
4-chloro-benzene-1,2-diamine (156 mg), and sodium metabisulfite
(280 mg) in DMA (2 mL) was heated to 100.degree. C. for 12 h. The
resulting mixture was chromatographed (1-7% 2M methanolic
ammonia/DCM), giving the title compound as a pink solid (191 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.99 (d, J=9.1 Hz, 2H), 7.54 (m,
1H), 7.51 (m, 1H), 7.21 (m, 1H), 7.09 (d, J=9.1 Hz, 2H), 4.51 (m,
1H), 2.84 (m, 2H), 2.77 (m, 1H), 2.51 (m, 2H), 2.07 (m, 2H), 1.82
(m, 2H), 1.10 (d, J=6.6 Hz, 6H).
Example 50
[0368] 65
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-[1,4]diazepane
[0369] A solution of the product of Example 2 (171 mg), N-methyl
homopiperazine (0.09 mL), and acetic acid (0.07 mL) in DCM (3 mL)
was treated with sodium triacetoxyborohydride (220 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (5 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (121 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.22 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 4.26
(m,1H), 3.55 (s, 2H), 2.82-2.72 (m, 3H), 2.71-2.63 (m, 6H),
2.61-2.57 (m, 2H), 2.41-2.36 (m, 2H), 2.35 (s, 3H), 2.00 (m, 2H),
1.85-1.76 (m, 4H), 1.06 (d, J=6.6 Hz, 6H).
Example 51
[0370] 66
Butyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine
[0371] A solution of the product of Example 2 (167 mg),
butyl-methyl-amine (0.08 mL), and acetic acid (0.07 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (220 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (157 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 4.27
(m,1H), 3.40 (s, 2H), 2.82-2.71 (m, 3H), 2.39 (m, 2H), 2.34 (m,
2H), 2.16 (s, 3H), 2.00 (m, 2H), 1.85-1.76 (m, 2H), 1.52-1.45 (m,
2H), 1.38-1.27 (m, 2H) 1.06 (d, J=6.6 Hz, 6H), 0.90 (t, J=7.3 Hz,
3H).
Example 52
[0372] 67
N-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-N,N',N'-trimethyl-ethane-1,2--
diamine
[0373] A solution of the product of Example 2 (171 mg),
N,N,N'-trimethyl-ethane-1,2-diamine (0.09 mL), and acetic acid
(0.07 mL) in DCM (3 mL) was treated with sodium
triacetoxyborohydride (220 mg). After 16 h, the resulting mixture
was treated with 10% sodium hydroxide (5 mL), and the mixture was
extracted with DCM (3.times.10 mL). The combined organic phases
were dried (sodium sulfate) and evaporated. Chromatography of the
residue (1-7% 2M methanolic ammonia/DCM) gave the title compound as
a clear oil (126 mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.19 (d,
J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 4.26 (m,1H), 3.44 (s, 2H),
2.82-2.71 (m, 3H), 2.48-2.34 (m, 6H), 2.22 (s, 3H), 2.20 (s, 6H),
2.04-1.96 (m, 2H), 1.85-1.75 (m, 2H), 1.06 (d, J=6.6 Hz, 6H).
Example 53
[0374] 68
Cyclohexyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-methyl-amine
[0375] A solution of the product of Example 2 (169 mg),
cyclohexyl-methyl-amine (0.09 mL), and acetic acid (0.07 mL) in DCM
(3 mL) was treated with sodium triacetoxyborohydride (220 mg).
After 16 h, the resulting mixture was treated with 10% sodium
hydroxide (5 mL), and the mixture was extracted with DCM
(3.times.10 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Chromatography of the residue (1-7% 2M
methanolic ammonia/DCM) gave the title compound as a clear oil (165
mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H),
6.84 (d, J=8.6 Hz, 2H), 4.26 (m,1H), 3.48 (s, 2H), 2.82-2.70 (m,
3H), 2.46-2.33 (m, 3H), 2.17 (s, 3H), 2.04-1.96 (m, 2H), 1.89-1.76
(m, 6H), 1.62 (m, 1H), 1.34-1.15 (m, 4H) 1.05 (d, J=6.6 Hz,
6H).
Example 54
[0376] 69
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane
[0377] A solution of the product of Example 2 (167 mg),
hexamethyleneimine (0.08 mL), and acetic acid (0.07 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (220 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (163 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.22 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 4.26
(m,1H), 3.56 (s, 2H), 2.85-2.71 (m, 3H), 2.60 (m, 4H), 2.38 (m,
2H), 2.04-1.96 (m, 2H), 1.85-1.76 (m, 2H), 1.60 (m, 9H), 1.06 (d,
J=6.6 Hz, 6H).
Example 55
[0378] 70
Diethyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine
[0379] A solution of the product of Example 2 (170 mg),
diethylamine (0.08 mL), and acetic acid (0.07 mL) in DCM (3 mL) was
treated with sodium triacetoxyborohydride (220 mg). After 16 h, the
resulting mixture was treated with 10% sodium hydroxide (5 mL), and
the mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (78 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.21 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 4.26
(m, 1H), 3.49 (s, 2H), 2.82-2.70 (m, 4H), 2.50 (q, J=7.1 Hz, 4H),
2.37 (m, 2H), 2.04-1.96 (m, 2H), 1.85-1.76 (m, 2H), 1.60 (m, 9H),
1.07-1.00 (m, 12H).
Example 56
[0380] 71
1-Isopropyl-4-(4-pyrrolidin-1-ylmethyl-phenoxy)-piperidine
[0381] A solution of the product of Example 2 (169 mg), pyrrolidine
(0.06 mL), and acetic acid (0.07 mL) in DCM (3 mL) was treated with
sodium triacetoxyborohydride (220 mg). After 16 h, the resulting
mixture was treated with 10% sodium hydroxide (5 mL), and the
mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (144 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.21 (d, J=8.8 Hz, 2H), 6.84 (d, J=8.8 Hz, 2H), 4.26
(m, 1H), 3.53 (s, 2H), 2.82-2.71 (m, 3H), 2.48 (m, 4H), 2.37 (m,
2H), 2.03-1.96 (m, 2H), 1.85-1.74 (m, 6H), 1.05 (d, J=6.6 Hz,
6H).
Example 57
[0382] 72
N-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-O,N-dimethyl-hydroxylamine
[0383] A solution of the product of Example 2 (170 mg) and
O,N-dimethyl-hydroxylamine hydrochloride (0.15 g) in DCM (3 mL) was
treated with sodium triacetoxyborohydride (220 mg). After 16 h, the
resulting mixture was treated with 10% sodium hydroxide (5 mL), and
the mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (179 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.24 (d, J=8.8 Hz, 2H), 6.85 (d, J=8.8 Hz, 2H), 4.27
(m,1H), 3.70 (s, 2H), 3.37 (s, 3H), 2.81-2.70 (m, 3H), 2.58 (s,
3H), 2.48 (m, 4H), 2.37 (m, 2H), 2.03-1.96 (m, 2H), 1.85-1.76 (m,
2H), 1.05 (d, J=6.6 Hz, 6H).
Example 58
[0384] 73
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-dimethyl-amine
[0385] A solution of the product of Example 2 (170 mg) and
dimethylamine hydrochloride (0.12 g) in DCM (3 mL) was treated with
sodium triacetoxyborohydride (220 mg). After 16 h, the resulting
mixture was treated with 10% sodium hydroxide (5 mL), and the
mixture was extracted with DCM (3.times.10 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (163 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.18 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 4.27
(m, 1H), 3.34 (s, 2H), 3.37 (s, 3H), 2.81-2.70 (m, 3H), 2.38 (m,
2H), 2.21 (s, 6H), 2.05-1.96 (m, 2H), 1.85-1.75 (m, 2H), 1.05 (d,
J=6.6 Hz, 6H).
Example 59
[0386] 74
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-methyl-piperazine
[0387] A solution of the product of Example 2 (173 mg),
N-methylpiperazine (0.08 mL), and acetic acid (0.08 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (220 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (217 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H), 6.83 (d, J=8.6 Hz, 2H), 4.26
(m, 1H), 3.42 (s, 2H), 2.81-2.70 (m, 3H), 2.55-2.33 (m, 8H), 2.26
(s, 3H), 2.03-1.97 (m, 2H), 1.84-1.74 (m, 2H), 1.04 (d, J=6.6 Hz,
6H).
Example 60
[0388] 75
4-[4-(4-Benzylidene-piperidin-1-ylmethyl)-phenoxy]-1-isopropyl-piperidine
[0389] A solution of the product of Example 2 (136 mg),
4-benzylidene-piperidine (94 mg), and acetic acid (0.05 mL) in DCM
(3 mL) was treated with sodium triacetoxyborohydride (190 mg).
After 16 h, the resulting mixture was treated with 10% sodium
hydroxide (5 mL), and the mixture was extracted with DCM
(3.times.10 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Chromatography of the residue (1-7% 2M
methanolic ammonia/DCM) gave the title compound as a clear oil (54
mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.32-7.27 (m, 2H),
7.23-7.16 (m, 5H), 6.86 (d, J=8.6 Hz, 2H), 6.27 (s, 1H), 4.28 (m,
1H), 3.46 (s, 2H), 2.83-2.71 (m, 3H), 2.54-2.49 (m, 4H), 2.43-2.35
(m, 6H), 2.05-1.97 (m, 2H), 1.86-1.76 (m, 2H), 1.06 (d, J=6.6 Hz,
6H).
Example 61
[0390] 76
1-Benzyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-piperazine
[0391] A solution of the product of Example 2 (188 mg),
N-benzylpiperazine (0.13 mL), and acetic acid (0.06 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (260 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (239 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.31-7.29 (m, 4H), 7.25-7.23 (m, 1H), 7.18 (d, J=8.6
Hz, 2H) 6.84 (d, J=8.6 Hz, 2H), 4.26 (m, 1H), 3.50 (s, 2H), 3.43
(s, 2H), 2.82-2.70 (m, 3H), 2.54-2.34 (m, 9H), 2.03-1.96 (m, 2H),
1.84-1.75 (m, 2H), 1.06 (d, J=6.6 Hz, 6H).
Example 62
[0392] 77
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-4-phenyl-piperazine
[0393] A solution of the product of Example 2 (140 mg),
N-phenylpiperazine (0.09 mL), and acetic acid (0.05 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (190 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (78 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.30-7.22 (m, 4H), 6.65-6.82 (m, 5H), 4.29 (m, 1H),
3.50 (s, 2H), 3.19 (m, 2H), 3.16-3.12 (m, 2H), 2.83-2.71 (m, 3H),
2.59 (m, 2H), 2.39 (m, 2H), 2.06-1.99 (m, 2H), 1.87-1.78 (m, 2H),
1.07 (d, J=6.6 Hz, 6H).
Example 63
[0394] 78
1-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-4-benzyl-piperidine
[0395] A solution of the product of Example 2 (188 mg),
N-benzylpiperidine (0.13 mL), and acetic acid (0.05 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (250 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (160 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.29-7.23 (m, 3H), 7.19-7.10 (m, 4H), 6.83 (m, 2H),
4.26 (m, 1H), 3.39 (s, 2H), 2.87-2.70 (m, 5H), 2.52 (d, J=7.1 Hz,
2H), 2.38 (m, 2H), 2.03-1.96 (m, 2H), 1.59 (m, 2H), 1.50 (m, 1H),
1.29 (m, 2H), 1.06 (d, J=6.6 Hz, 6H).
Example 64
[0396] 79
Cyclopropyl-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-amine
[0397] A solution of the product of Example 2 (250 mg),
cyclopropylamine (0.10 mL), and acetic acid (0.07 mL) in DCM (3 mL)
was treated with sodium triacetoxyborohydride (340 mg). After 16 h,
the resulting mixture was treated with 10% sodium hydroxide (5 mL),
and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (88 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.19 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 4.25
(m,1H), 3.74 (s, 2H), 2.81-2.69 (m, 3H), 2.37 (m, 2H), 2.12 (m,
1H), 2.03-1.95 (m, 2H), 1.83-1.74 (m, 2H), 1.04 (d, J=6.6 Hz, 6H),
0.44-0.33 (m, 4H).
Example 65
[0398] 80
[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-methyl-(1-methyl-piperidin-4-yl-
)-amine
[0399] A solution of the product of Example 2 (146 mg),
1-methyl-4-(methylamino)piperidine (0.09 mL), and acetic acid (0.09
mL) in DCM (3 mL) was treated with sodium triacetoxyborohydride
(200 mg). After 16 h, the resulting mixture was treated with 10%
sodium hydroxide (5 mL), and the mixture was extracted with DCM
(3.times.10 mL). The combined organic phases were dried (sodium
sulfate) and evaporated. Chromatography of the residue (1-7% 2M
methanolic ammonia/DCM) gave the title compound as a clear oil (137
mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.16 (d, J=8.6 Hz, 2H),
6.82 (d, J=8.6 Hz, 2H), 4.24 (m, 1H), 3.47 (s, 2H), 2.88 (m, 2H),
2.79-2.68 (m, 3H), 2.43-2.32 (m, 3H), 2.23 (s, 3H), 2.15 (s, 3H),
2.01-1.94 (m, 2H), 1.89 (m, 2H), 1.82-1.73 (m, 4H), 1.69-1.59 (m,
2H) 1.03 (d, J=6.6 Hz, 6H).
Example 66
[0400] 81
{1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidin-4-yl}-methanol
[0401] A solution of the product of Example 2 (158 mg),
4-piperidinemethanol (78 mg), and acetic acid (0.08 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (220 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (166 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.17 (d, J=8.6 Hz, 2H), 6.82 (d, J=8.6 Hz, 2H), 4.25
(m,1H), 3.24 (d, J=6.6 Hz, 2H), 3.39 (s, 2H), 2,87 (m, 2H),
2.80-2.69 (m, 3H), 2.37 (m, 2H), 2.02-1.94 (m, 2H), 1.90 (m, 2H),
1.83-1.74 (m, 2H), 1.69 (m, 2H) 1.45 (m, 1H), 1.23 (m, 2H), 1.04
(d, J=6.6 Hz, 6H).
Example 67
[0402] 82
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidin-4-ol
[0403] A solution of the product of Example 2 (167 mg),
4-hydroxypiperidine (73 mg), and acetic acid (0.08 mL) in DCM (3
mL) was treated with sodium triacetoxyborohydride (220 mg). After
16 h, the resulting mixture was treated with 10% sodium hydroxide
(5 mL), and the mixture was extracted with DCM (3.times.10 mL). The
combined organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (168 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.17 (d, J=8.6 Hz, 2H), 6.82 (d, J=8.6 Hz, 2H), 4.25
(m, 1H), 3.64 (m, 1H), 3.42 (s, 1H), 3.40 (s, 2H), 2.80-2.69 (m,
5H), 2.36 (m, 2H), 2.08 (m, 2H), 2.02-1.94 (m, 2H), 1.87-1.74 (m,
2H), 1.55 (m, 2H), 1.04 (d, J=6.6 Hz, 6H).
Example 68
[0404] 83
4-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-morpholine
[0405] A solution of the product of Example 2 (360 mg), morpholine
(0.13 mL), and acetic acid (0.09 mL) in DCM (5 mL) was treated with
sodium triacetoxyborohydride (450 mg). After 16 h, the resulting
mixture was treated with 10% sodium hydroxide (10 mL), and the
mixture was extracted with DCM (3.times.20 mL). The combined
organic phases were dried (sodium sulfate) and evaporated.
Chromatography of the residue (1-7% 2M methanolic ammonia/DCM) gave
the title compound as a clear oil (366 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.20 (d, J=8.6 Hz, 2H), 6.82 (d, J=8.6 Hz, 2H), 4.27
(m, 1H), 3.69 (m, 4H), 3.42 (s, 2H), 2.82-2.70 (m, 3H), 2.41 (m,
4H), 2.36 (m, 2H), 2.04-1.96 (m, 2H), 1.84-1.75 (m, 2H), 1.05 (d,
J=6.6 Hz, 6H).
Example 69
[0406] 84
1-[4-(1-Isopropyl-piperidin-4-ylmethoxy)-benzyl]-piperidine
[0407] A solution of 4-hydroxymethylpiperidine (23.1 g), acetone
(40 mL), acetic acid (12 mL) and sodium triacetoxyborohydride (62
g) in DCM (3 mL) was stirred under nitrogen overnight at room
temperature. The reaction mixture was basified with 10% aqueous
sodium hydroxide to a pH of 12-13. The resulting mixture was
extracted with dichloromethane (3.times.150 mL). The combined
extracts were dried (sodium sulfate), filtered and evaporated,
yielding an oil (31.47 g). A portion of this oil (595 mg) was added
to a suspension of sodium hydride (151 mg) in dimethyl formamide (4
mL) under nitrogen. After 30 min, a solution of
4-cyanochlorobenzene (521 mg) in dimethyl formamide (2 mL) was
added. The reaction mixture was heated to 65-68.degree. C. for 18
hours, cooled to RT, and poured into water (200 mL). The resulting
mixture was extracted with ethyl acetate (3.times.30 mL). The
combined extracts were washed with water, brine and water and then
dried (sodium sulfate). The residue was chromatographed (5% 2 M
methanolic ammonia/DCM). This product (230 mg) was then dissolved
in toluene, cooled to 0.degree. C., and treated with di-isobutyl
aluminum hydride (2.2 mL of a 1 M solution in hexane). The reaction
mixture was warmed to RT, stirred for 16 hours, and quenched with
ethyl acetate (1 mL). Sodium hydroxide (20 mL of a 1 M aqueous
solution) was added, and the resulting mixture was stirred for five
minutes and then extracted with DCM (2.times.30 mL). The combined
organic phases were evaporated, and the residue was chromatographed
(5% 2 M methanolic ammonia/DCM). A suspension of this product (100
mg), piperidine (38 .mu.L), acetic acid (22 .mu.L) and sodium
triacetoxyborohydride (122 mg) in DCE (3 mL) was stirred overnight.
The reaction mixture was quenched with 1 N aqueous sodium hydroxide
(1 mL) and extracted with DCM (3.times.20 mL). The combined
extracts were evaporated to dryness. Chromatography of the residue
(5% 2 M methanolic ammonia/DCM) yielded the title compound (13 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.20 (d, J=8.59 Hz, 2 H), 6.83
(d, J=8.6 Hz, 2 H), 3.78 (d, J=6.3 Hz, 2 H), 2.95 (d, J=12Hz, 2 H),
2.75 (m, 1 H), 2.37 (brs, 4 H), 2.19 (m, 3 H), 1.83 (m,4 H), 1.57
(m, 4 H), 1.42 (m, 4 H), 1.08 (d, J=6.6 Hz, 6 H).
Example 70
[0408] 85
4-(1-Isopropyl-piperidin-4-yloxy)-benzonitrile
[0409] A solution of the product of Example 3 (10.74 g) and
4-Chloro-benzonitrile (11.45 g) in DMF (100 mL) was treated with
NaH (60%, 3.7 g). The resulting dark mixture was then heated to
65.degree. C. for 16 h, and allowed to cool to RT. The mixture was
poured into water (1.5 L) and extracted with ether (3.times.400
mL). The combined organic phases were dried (sodium sulfate) and
evaporated which gave the title compound as a light brown solid
(16.6 g). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.56 (d, J=8.6 Hz,
2H), 6.93 (d, J=8.6 Hz, 2H), 4.37 (m,1H), 2.81-2.72 (m, 3H), 2.41
(m, 4H), 2.06-1.98 (m, 2H), 1.87-1.77 (m, 2H), 1.06 (d, J=6.6 Hz,
6H).
Example 71
[0410] 86
1-Isopropyl-4-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-piperazine
[0411] A solution of the product of Example 74 (0.061 mg), acetone
(2 mL), and acetic acid (0.012 mL) in DCM (10 mL) was treated with
sodium triacetoxyborohydride (59 mg). After 16 h, the resulting
mixture was treated with 10% aqueous sodium hydroxide (5 mL). The
aqueous phase was extracted with DCM (2.times.50 mL). The combined
organic phases were washed with water (10 mL), brine (10 mL), dried
(magnesium sulfate), and evaporated. Chromatography of the residue
(4-10% 2M methanolic ammonia) gave the title compound as a
colorless solid (40 mg). .sup.1H NMR (400 MHz, CDCl.sub.3):
6.90-6.83 (m, 4H), 4.19-4.15 (m,1H), 3.11 (t, J=5.0 Hz, 4H),
2.81-2.67 (m, 8H), 2.38-2.33 (m, 2H), 2.02-1.95 (m, 2H), 1.82-1.74
(m, 2H), 1.09 (d, J=6.5 Hz, 6H), 1.05 (d, J=6.6 Hz, 6H).
Example 72
[0412] 87
1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidine
[0413] A suspension of the product of Example 3 (129 mg), the
product of Example 1 (172 mg), and polymer-supported
triphenylphosphine (600 mg) in DCM (5 mL) was treated with
di-tert-butyl azodicarboxylate (311 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM), giving the title
compound as a colorless oil (75 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.19 (d, J=8.5 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H),
4.29-4.25 (m, 1H), 3.40 (s, 2H), 2.82-2.71 (m, 3H), 2.41-2.35 (m,
6H), 2.40-2.26 (m, 6H), 2.03-1.99 (m, 2H), 1.85-1.77 (m, 2H),
1.59-1.53 (m, 4H), 1.43-1.38 (m, 2H), 1.06 (d, J=6.6 Hz, 6H),
Example 73
[0414] 88
1-Isopropyl-4-(4-pyrrol-1-yl-phenoxy)-piperidine
[0415] A suspension of the product of Example 3 (129 mg),
4-(1H-pyrrol)-1-yl)phenol (143 mg), and polymer-supported
triphenylphosphine (600 mg) in DCM (5 mL) was treated with
di-tert-butyl azodicarboxylate (311 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM), giving the title
compound as a light yellow oil (92 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.27 (d, J=8.9 Hz, 2H), 6.99-6.98 (m, 2H), 6.93 (d,
J=8.9 Hz, 2H), 6.31-6.30 (m, 2H), 4.30-4.26 (m, 1H), 2.82-2.71 (m,
3H), 2.42-2.36 (m, 2H), 2.04-2.00 (m, 2H), 1.86-1.78 (m, 2H), 1.06
(d, J=6.6 Hz, 6H).
Example 74
[0416] 89
1-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-piperazine
[0417] A solution of 1-(4-hydroxyphenyl)-piperazine (12.0 g) in THF
(50 mL) was treated with di-tert butyl dicarbonate (72 mL of a 1 M
solution in THF). After 10 min, saturated aqueous sodium
bicarbonate was added. After 16 h, the resulting mixture was
extracted with ethyl acetate (1.5 L). The organic phase was washed
with water (2.times.200 mL), brine (200 mL), and then dried
(magnesium sulfate) and evaporated. The resulting brown oil was
triturated with hexane, giving a brown solid (16.3 g). A suspension
of this brown solid (501 mg), the product of Example 66 (258 mg),
and polymer-supported triphenylphosphine (1.2 g) in DCM (12 mL) was
treated with di-tert-butyl azodicarboxylate (622 mg). The resulting
mixture was shaken for 16 h and filtered through a pad of celite.
The pad was washed with DCM (3.times.2 mL) and the combined
filtrates were chromatographed (1-6% 2 M methanolic ammonia/DCM)
giving the title compound as a brown oil (275 mg). A solution of
this brown oil (259 mg) in dioxane (5 mL) was treated with hydrogen
chloride (5 mL of a 4 N solution in dioxane). After 16 h solvent
was evaporated and the residue was treated with 10% aqueous sodium
hydroxide (20 mL) and extracted with DCM (2.times.100 mL). The
combined organic phases were washed with water (50 mL), brine (50
mL), and dried (magnesium sulfate) and evaporated. Chromatography
of the residue (6-20% 2 M methanolic ammonia/DCM) gave the title
compound as a colorless oil (61 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 6.89-6.83 (m, 4H), 4.21-4.15 (m, 1H), 3.03 (s, 8H),
2.82-2.72 (m, 3H), 2.41-2.35 (m, 2H), 2.03-1.97 (m, 2H), 1.83-1.75
(m, 2H), 1.06 (d, J=6.6 Hz, 6H).
Example 75
[0418] 90
[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-phenyl-methanol
[0419] A solution of the product of Example 75 (65 mg) in ethanol
(10 mL) was treated with sodium borohyd ride (1 g). After 16 h, the
resulting mixture was treated with saturated aqueous sodium
bicarbonate (20 mL), and extracted with DCM (2.times.50 mL). The
combined organic phases were dried (magnesium sulfate) and
evaporated. Chromatography of the residue (1-10% 2 M methanolic
ammonia/DCM) gave the title compound as a colorless oil (52 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.38-7.21 (m, 7H), 6.86-6.82 (m,
2H), 5.76 (s, 1H), 4.27-4.23 (m, 1H), 2.77-2.68 (m, 3H), 2.39-2.34
(m, 2H), 2.01-1.96 (m, 2H), 1.81-1.72 (m, 2H), 1.04 (d, J=6.6 Hz,
6H).
Example 76
[0420] 91
[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-phenyl-methanone
[0421] A suspension of the product of Example 66 (258 mg),
4-hydroxybenzophenone (357 mg), and polymer-supported
triphenylphosphine (1.2 g) in DCM (6 mL) was treated with
di-tert-butyl azodicarboxylate (622 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM) giving the title
compound as a colorless oil (151 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.81 (d, J=8.9 Hz, 2H), 7.76-7.74 (m, 2H), 7.59-7.54
(m, 1H), 6.96 (d, J=8.8 Hz, 2H), 4.46-4.40 (m, 1H), 2.83-2.73 (m,
3H), 2.46-2.40 (m, 2H), 2.08-2.03 (m, 2H), 1.90-1.82 (m, 2H), 1.07
(d, J=6.5 Hz, 6H).
Example 77
[0422] 92
N-Isopropyl-4-{4-[5-(1-isopropyl-piperidin-4-ylsulfanyl)-tetrazol-1-yl]-ph-
enoxy}-piperidine
[0423] A suspension of the product of Example 66 (258 mg),
1-(4-hydroxyphenyl)-1H-tetrazole-5-thiol (175 mg), and
polymer-supported triphenylphosphine (1.2 g) in DCM (6 mL) was
treated with di-tert-butyl azodicarboxylate (622 mg). The resulting
mixture was shaken for 16 h and filtered through a pad of celite.
The pad was washed with DCM (3.times.1 mL) and the combined
filtrates were chromatographed (1-6% 2 M methanolic ammonia/DCM)
giving the title compound as a colorless oil (54 mg). .sup.1H NMR
(400 MHz, CDCl.sub.3): 7.44-7.41 (m, 2H), 7.05-7.02 (m, 2H),
4.39-4.36 (m, 1H), 3.97-3.92(m, 1H), 2.86-2.70 (m, 6H), 2.46-2.40
(m, 4H), 2.38-2.24 (m, 2H), 2.07-2.03 (m, 2H), 1.89-1.74 (m, 4H),
1.07 (d, J=6.5 Hz, 6H), 1.04 (d, J=6.6 Hz, 6H).
Example 78
[0424] 93
4-(4-Imidazol-1-yl-phenoxy)-1-isopropyl-piperidine
[0425] A suspension of the product of Example 66 (258 mg),
4-(imidazol-1-yl)phenol (144 mg), and polymer-supported
triphenylphosphine (1.2 g) in DCM (6 mL) was treated with
di-tert-butyl azodicarboxylate (622 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM) giving the title
compound as a colorless oil (67 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.76 (s, 1H), 7.30-7.26 (m, 2H), 7.21-7.18 (m, 2H),
7.01-6.97 (m, 2H), 4.36-4.30 (m, 1H), 2.85-2.75 (m, 3H), 2.44-2.39
(m, 2H), 2.07-2.01 (m, 2H), 1.88-1.80 (m, 2H), 1.07 (d, J=6.6 Hz,
6H).
Example 79
[0426] 94
N-[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-acetamide
[0427] A suspension of the product of Example 66 (258 mg),
acetaminophen (136 mg), and polymer-supported triphenylphosphine
(1.2 g) in DCM (6 mL) was treated with di-tert-butyl
azodicarboxylate (622 mg). The resulting mixture was shaken for 16
h and filtered through a pad of celite. The pad was washed with DCM
(3.times.1 mL) and the combined filtrates were chromatographed
(1-6% 2 M methanolic ammonia/DCM) giving the title compound as a
colorless oil (82 mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 8.14 (s,
1H), 7.39-7.35 (m, 2H), 6.84-6.80 (m, 2H), 4.24-4.18 (m, 1H),
2.80-2.72 (m, 3H), 2.39-2.33 (m, 2H), 2.10 (s, 3H), 2.00-1.95 (m,
2H), 1.81-1.73 (m, 2H), 1.05 (d, J=6.6 Hz, 6H).
Example 80
[0428] 95
4-(4-Cyclopentyl-phenoxy)-1-isopropyl-piperidine
[0429] A suspension of the product of Example 66 (258 mg),
4-cyclopentylphenol (146 mg), and polymer-supported
triphenylphosphine (1.2 g) in DCM (6 mL) was treated with
di-tert-butyl azodicarboxylate (622 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM) giving the title
compound as a colorless oil (19 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.15-7.12 (m, 2H), 6.85-6.81 (m, 2H), 4.28-4.22 (m,
1H), 2.97-2.88 (m, 1H), 2.42-2.36 (m, 2H), 2.07-1.99 (m, 4H),
1.85-1.49 (m, 8H), 1.06 (d, J=6.6 Hz, 6H).
Example 81
[0430] 96
[4-(1-Isopropyl-piperidin-4-yloxy)-phenyl]-phenyl-amine
[0431] A suspension of the product of Example 66 (258 mg),
4-hydroxydiphenylamine (136 mg), and polymer-supported
triphenylphosphine (1.2 g) in DCM (6 mL) was treated with
di-tert-butyl azodicarboxylate (622 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM) giving the title
compound as a brown oil (25 mg). .sup.1H NMR (400 MHz, CDCl.sub.3):
7.23-7.19 (m, 2H), 7.06-7.03 (m, 2H), 6.93-6.91 (m, 2H), 6.88-6.81
(m, 3H), 4.26-4.20 (m,1H), 2.84-2.74 (m, 3H), 2.44-2.38 (m, 2H),
2.06-2.00 (m, 2H), 1.07 (d, J=6.6 Hz, 6H).
Example 82
[0432] 97
4-(4-Benzyloxy-phenoxy)-1-isopropyl-piperidine
[0433] A suspension of the product of Example 66 (258 mg),
4-(benzyloxy)phenol (180 mg), and polymer-supported
triphenylphosphine (1.2 g) in DCM (6 mL) was treated with
di-tert-butyl azodicarboxylate (622 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM) giving the title
compound as a light pink solid (102 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.43-7.28 (m, 5H), 6.91-6.82 (m, 4H), 5.00 (s, 2H),
4.18-4.13 (m, 1H), 2.81-2.69 (m, 3H), 2.38-2.32 (m, 2H), 2.01-1.95
(m, 2H), 1.82-1.74 (m, 2H), 1.05 (d, J=6.6 Hz, 6H).
Example 83
[0434] 98
1-Isopropyl-4-(4-phenoxy-phenoxy)-piperidine
[0435] A suspension of the product of Example 66 (258 mg),
4-phenoxyphenol (168 mg), and polymer-supported triphenylphosphine
(1.2 g) in DCM (6 mL) was treated with di-tert-butyl
azodicarboxylate (622 mg). The resulting mixture was shaken for 16
h and filtered through a pad of celite. The pad was washed with DCM
(3.times.1 mL) and the combined filtrates were chromatographed
(1-6% 2 M methanolic ammonia/DCM) giving the title compound as a
colorless oil (77 mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.31-7.26
(m, 2H), 7.05-7.01 (m, 1H), 6.97-6.92 (m, 4H), 6.90-6.86 (m, 2H),
4.25-4.20 (m,1H), 2.83-2.72 (m, 3H), 2.41-2.35 (m, 2H), 2.05-1.99
(m, 2H), 1.86-1.77 (m, 2H), 1.06 (d, J=6.6 Hz, 6H).
Example 84
[0436] 99
4-(4-Benzyl-phenoxy)-1-isopropyl-piperidine
[0437] A suspension of the product of Example 66 (258 mg),
4-hydroxydiphenylmethane (166 mg), and polymer-supported
triphenylphosphine (1.2 g) in DCM (6 mL) was treated with
di-tert-butyl azodicarboxylate (622 mg). The resulting mixture was
shaken for 16 h and filtered through a pad of celite. The pad was
washed with DCM (3.times.1 mL) and the combined filtrates were
chromatographed (1-6% 2 M methanolic ammonia/DCM) giving the title
compound as a light yellow oil (108 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.30-7.26 (m, 2H), 7.20-7.16 (m, 3H), 7.09-7.06 (m,
2H), 6.84-6.81 (m, 2H), 4.27-4.21 (m, 1H), 3.91 (s, 2H), 2.81-2.67
(m, 3H), 2.40-2.34 (m, 2H), 2.02-1.92 (m, 2H), 1.83-1.75 (m, 2H),
1.05 (d, J=6.6 Hz, 6H).
Example 85
[0438] 100
4-(Biphenyl-4-yloxy)-1-isopropyl-piperidine
[0439] A suspension of the product of Example 66 (258 mg), acetone
(0.039 mL), and polymer-supported triphenylphosphine (1.2 g) in DCM
(6 mL) was treated with di-tert-butyl azodicarboxylate (622 mg).
The resulting mixture was shaken for 16 h and filtered through a
pad of celite. The pad was washed with DCM (3.times.1 mL) and the
combined filtrates were chromatographed (1-6% 2 M methanolic
ammonia/DCM) giving the title compound as a white solid (91 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.55-7.49 (m, 4H), 7.42-7.38 (m,
2H), 7.30-7.26 (m, 1H), 6.98-6.95 (m, 2H), 4.36-4.31 (m, 1H),
2.83-2.73 (m, 3H), 2.46-2.41 (m, 2H), 2.09-2.05 (m, 2H), 1.90-1.82
(m, 2H), 1.08 (d, J=6.6 Hz, 6H).
Example 86
[0440] 101
4-(Biphenyl-4-yloxy)-piperidine
[0441] A suspension of tert-butyl 4-hydroxy-1-piperidine
carboxylate (497 mg), 4-phenylphenol (300 mg), and
polymer-supported triphenylphosphine (1.2 g) in DCM (10 mL) was
treated with di-tert-butyl azodicarboxylate (608 mg). The resulting
mixture was shaken for 16 h, and filtered through a pad of celite.
The pad was washed with DCM (3.times.5 mL) and the combined
filtrates were evaporated. The residue was dissolved in dioxane (5
mL) and treated with hydrogen chloride (5 mL of a 4 N solution in
dioxane). After 16 h, solvent was removed and the residue was
treated with 10% aqueous sodium hydroxide (20 mL). The resulting
mixture was extracted with DCM (2.times.500 mL), and the combined
organic phases were dried (magnesium sulfate) and evaporated.
Chromatography of the residue (1-6% 2M methanolic ammonia/DCM) gave
the title compound as a white solid (107 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.56-7.49 (m, 4H), 7.42-7.39 (m, 2H), 7.31-7.27
(m,1H), 6.99-6.96 (m, 2H), 4.43-4.37 (m, 1H), 3.18-3.13 (m, 3H),
2.77-2.70 (m, 2H), 2.07-2.01 (m, 2H), 1.73-1.64 (m, 2H).
Example 87
Biological Methods
In Vitro
[0442] Transfection of Cells with Human Histamine Receptor
[0443] A 10 cm tissue culture dish with a confluent monolayer of
SK-N-MC cells was split two days prior to transfection. Using
sterile technique the media was removed and the cells were detached
from the dish by the addition of trypsin. One fifth of the cells
were then placed onto a new 10 cm dish. Cells were grown in a
37.degree. C. incubator with 5% CO.sub.2 in Minimal Essential Media
Eagle with 10% Fetal Bovine Serum. After two days cells were
approximately 80% confluent. These were removed from the dish with
trypsin and pelleted in a clinical centrifuge. The pellet was then
re-suspended in 400 .mu.L complete media and transferred to an
electroporation cuvette with a 0.4 cm gap between the electrodes
(Bio-Rad #165-2088). One microgram of supercoiled H.sub.3 receptor
cDNA was added to the cells and mixed. The voltage for the
electroporation was set at 0.25 kV, the capacitance was set at 960
.mu.F. After electroporation the cells were diluted into 10 mL
complete media and plated onto four 10 cm dishes. Because of the
variability in the efficiency of electroporation, four different
concentrations of cells were plated. The ratios used were; 1:20,
1:10, 1:5, with the remainder of the cells being added to the
fourth dish. The cells were allowed to recover for 24 hours before
adding the selection media (complete media with 600 .mu.g/mL G418).
After 10 days dishes were analyzed for surviving colonies of cells.
Dishes with well isolated colonies were used. Cells from individual
colonies were isolated and tested. SK-N-MC cells were used because
they give efficient coupling for inhibition of adenylate cyclase.
The clones that gave the most robust inhibition of adenylate
cyclase in response to histamine were used for further study.
[0444] [.sup.3H]-N-methylhistamine Binding
[0445] Cell pellets from histamine H.sub.3 receptor-expressing
SK-N-MC cells were homogenized in 20 mM TrisHCl/0.5 mM EDTA.
Supernatants from a 800 g spin were collected, recentrifuged at
30,000 g for 30 minutes. Pellets were re-homogenized in 50 mM
Tris/5 mM EDTA (pH 7.4). Membranes were incubated with 0.8 nM
[.sup.3H]-N-methylhistamine plus/minus test compounds for 45 min at
25.degree. C. and harvested by rapid filtration over GF/C glass
fiber filters (pretreated with 0.3% polyethylenimine) followed by
four washes with ice cold buffer. Filters were dried, added to 4 mL
scintillation cocktail and then counted on a liquid scintillation
counter. Non-specific binding was defined with 10 .mu.M histamine.
The pK.sub.i values were calculated based on a K.sub.d of 800 pM
and a ligand concentration ([L]) of 800 pM according to the
formula:
K.sub.i=(IC.sub.50)/(1+([L]/(K.sub.d))
In Vivo
[0446] Elucidation of Oral Absorption and Blood-brain Barrier
Penetration Profiles of H.sub.3 Receptor Antagonists in the Rat
[0447] A rat in vivo system was used to determine the blood-brain
barrier penetration profiles and kinetics of various H.sub.3
receptor antagonists after single bolus oral administration.
[0448] Female Sprague Dawley Rats (.about.300 gram body weight)
were housed in accordance with institutional standards and allowed
to acclimate for at least 7 days prior to the study. Each H.sub.3
antagonist was formulated in 0.5% hydroxypropylmethyl cellulose at
a concentration of 1 mg/mL for oral dosing. The test compound was
administered to each of eight animals as a single oral dose of 10
mL/kg (10 mg/kg). Remaining dosing solution was retained for
analysis. Two animals from each original group of eight were
euthanized via CO.sub.2 asphyxiation at t=1, 6, 24, and 48 hours.
After each animal was euthanized, 0.1 mL of its blood was sampled
via cardiac puncture, and its brain was removed via dissection of
the cranial bones and placed in a pre-weighed 50 mL conical tube on
dry ice.
[0449] The blood was added to 0.3 mL of 6% trichloroacetic acid,
and the acidified sample was vortexed and then centrifuged (5
minutes at 14,000 rpm in a microcentrifuge). The clear supernatant
was retained for analysis. The frozen brain was weighed,
homogenized in 6% trichloroacetic acid (3 mL/g wet weight of
tissue), and then centrifuged. The clear supernatant was retained
for analysis. The supernatants from the blood and brain samples
were analyzed by liquid chromatography with mass spectral detection
utilizing selective reaction monitoring (LC-MS/MS). The LC method
used a Phenomonex Polar RP column (2.times.50 mm) and a linear
solvent gradient of water and acetonitrile (both 1% in acetic
acid).
[0450] Graphs of H.sub.3 receptor antagonist concentration versus
time for blood and brain were generated from the LC-MS/MS results.
The mean residency time (MRT) of the H.sub.3 receptor antagonist,
in blood or in the brain, was calculated from the ratio of the area
under the first moment curve (AUMC) to the area under the
concentration time curve (AUC): AUMC/AUC. The Blood Brain Barrier
index was calculated from the log of
AUC.sub.brain/AUC.sub.blood.
[0451] F. Other Embodiments
[0452] The features and advantages of the invention will be
apparent to one of ordinary skill in view of the discussion,
examples, embodiments, and claims relating to the invention. The
invention also contemplates variations and adaptations, based on
the disclosure herein concerning the key features and advantages of
the invention, and within the abilities of one of ordinary
skill.
* * * * *